The assessment of pheophorbide a ethanolamide as a potential dual action anti cancer photosensitizer : = Évaluation de l'éthanolamide du phéophorbide a comme photosensibilisateur anti-cancérigène à double action by Weagle, Glenn
UNIVERSITÉ DU QUÉBEC 
THÈSE PRÉSENTÉE À 
L'UNIVERSITÉ DU QUÉBEC À TROIS-RIVIÈRES 
COMME EXIGENCE PARTIELLE 
DU DOCTORAT EN BIOPHYSIQUE 
PAR 
GLENN WEAGLE 
THE ASSESSMENT OF PHEOPHORBIDE a ETHANOLAMIDE 
AS A POTENTIAL DUAL ACTION ANTI CANCER PHOTOSENSITIZER 
(ÉVALUATION DE l'ÉTHANOLAMIDE DU PHÉOPHORBIDE a COMME 
PHOTOSENSIBILISATEUR ANTI-CANCÉRIGÈNE À DOUBLE ACTION) 
AOÛT 1995 
  
 
 
 
Université du Québec à Trois-Rivières 
Service de la bibliothèque 
 
 
Avertissement 
 
 
L’auteur de ce mémoire ou de cette thèse a autorisé l’Université du Québec 
à Trois-Rivières à diffuser, à des fins non lucratives, une copie de son 
mémoire ou de sa thèse. 
Cette diffusion n’entraîne pas une renonciation de la part de l’auteur à ses 
droits de propriété intellectuelle, incluant le droit d’auteur, sur ce mémoire 
ou cette thèse. Notamment, la reproduction ou la publication de la totalité 
ou d’une partie importante de ce mémoire ou de cette thèse requiert son 
autorisation.  
11 
Résumé 
Quelques grammes du phéophorbide a ethanolamide (PEA), un nouveau 
médicament potentiellement anti-cancereux à double action, présentant des propriétés 
chimio- et photochimiothérapeutique, a été synthétisée en trois étapes à partir de la 
chlorophylle a . La structure du PEA a été confirmée par spectroscopie électronique, 
infrarouge et résonance magnétique nucléaire. Sa pureté fut vérifiée par chromatographie 
liquide à haute pression. 
La dose létale pour tuer 50% des sujets sous observations (DL5o) du PEA est plus 
grande que 500 mg/kg. Ceci indique une faible toxicité et un indice thérapeutique élevé. 
En l'absence de lumière excitatrice le PEA montre une activité chimiothérapeutique chez 
des souris porteuses de tumeurs. Le PEA, présent en concentration dix fois supérieure à 
la dose d' adriamycine, produit, in vitro, un effet cytotoxique comparable sur les tissus 
humains cancéreux. 
Le traitement chimiothérapeutique avec le PEA sur des souris B6D2F 1 porteuses 
du carcinôme pulmonaire de Lewis a accru le délai avant la mort par un facteur de 2,5 
par rapport à des souris témoins. L'activité chimiothérapeutique peut être due à l' action 
d' alkylation du groupe ethanolamide dont la structure chimique est similaire à la partie 
active des agents moutardes azotés. Alors que les doses utilisées dans cette étude étaient 
insuffisantes pour éradiquer les cancers, le PEA semblait réduire les possibilités 
d'apparition de métastases chez des animaux porteurs du carcinôme pulmonaire de Lewis. 
La fluorescence du PEA a été utilisée pour suivre la pharmacocinétique du 
médicament. Lorsque les injections de PEA étaient intrapéritonéales ou intraveineuses 
dans la souris porteuse d' une tumeur (l'adénocarcinôme pulmonaire M4898 chez des 
souris Balb c), le temps de fluorescence maximum dans la tumeur était de 3 heures après 
l ' injection, et le rapport de la fluo-rescence provenant de la tumeur et du muscle était de 
6,7, montrant que le PEA présente une bonne sélectivité pour les tissus néoplastiques. Le 
temps de disparition du PEA dans la peau est de 24 h, ce qui implique que la 
photosensibilité de la peau est réduite à un minimum, contrairement à plusieurs 
médicaments PTD. 
La photohémolyse est une méthode qui peut être utilisée pour évaluer l' activité 
photosensibilisatrice de nouveaux photosensibilisateurs potentiels. Le PEA a montré des 
effets photohémolytiques probants en présentant un accroissement d' activité de 200 % en 
comparaison de la polyhématoporphyrine (pHP), un agent PTD disponible couramment, 
à des concentrations physiologiquement appropriées. 
Le PEA peut donc être considéré comme un nouvel agent anti-tumeur à double 
action, présentant une activité à la fois chimio- et photochimiothérapeutique. 
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Abstract 
Pheophorbide a ethanolamide, a new potential dual action anti-cancer drug 
exhibiting chemo- and photochemotherapeutic properties, was synthesized in gram 
quantities In three steps from chlorophyll a. The structure of pheophorbide a 
ethanolamide was confirmed by electronic, Fourier transform infrared and nuclear 
magnetic resonance spectroscopy, and its purity was confirmed by high performance 
liquid chromatography. 
The lethal dose 50% for pheophrobide a ethanolamide was greater than 500 mg 
kg-1 indicating low toxicity and high therapeutic index. Pheophorbide a ethanolamide 
showed chemotherapeutic activity in tumour-bearing mice in the absence of activating 
light. At about 10 times the concentration of adriamycin, pheophorbide a ethanolamide 
exhibited a comparable cytotoxic effect on human cancer cell lines in vitro. 
Chemotherapeutic treatment with pheophorbide a ethanolamide on B6D2F 1 mi ce with 
Lewis lung carcinoma increased the time to death by a factor of 2.5. The 
chemotherapeutic activity may be due to the alkylating action of the ethanolamide moiety, 
which is similar in chemical structure to the active component of nitrogen mustards. 
While the low doses used in this study were insufficient to eradicate the cancers, 
pheophorbide a ethanolamide appeared to reduce the likelihood of metastasis in Lewis 
lung cancer-bearing animaIs. 
The fluorescence of pheophorbide a ethanolamide was used to monitor the drug's 
pharmacokinetics. When pheophorbide a ethanolamide was injected intraperitoneally or 
intravenously into tumour bearing mice (M4898 Lung adenocarcinoma in Balb c mice), 
the time of maximum fluorescence in the tumour was at 3 hours post injection, and the 
tumour to muscle fluorescence ratio was 6.7, showing that pheophorbide a ethanolamide 
exhibited good selectivity for neoplastic tissue. The observed skin clearance time of 24 
hours for pheophorbide a ethanolamide implies that skin photosensitivity would be 
minimal unlike many photodynamic therapy drugs. 
Photohemolysis is a method that can be used to evaluate the photosensitizing 
activity of new potential photodynamic photosensitizers. pheophorbide a ethanolamide 
demonstrated efficient photohemolytic effects when irradiated with light, with a 200% 
increase in activity compared to polyhematoporphyrin, a currently available photodyamic 
therapy agent, at physiologically relevant concentrations. 
Pheophorbide a ethanolamide can thus be considered a new dual action antitumour 
agent, exhibiting both chemo- and photochemotherapeutic activity . 
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Chapter 1 General introduction 
1.1 Cyclic tetrapyrroles 
Cyclic tetrapyrroles have been extensively studied for their potential medical use. 
The cyclic tetrapyrroles are based on an eighteen (18) membered ring, where four (4) 
pyrrole subunits are joined together with methine bridges into a ring system (Fig. l.1) . 
Their molecular structure can be described as a rather flat molecular tablet that is 
approximately 49Â squared with a large central hole which can be occupied by a metal 
ligand. This unique structure has a conjugated double bond resonance system, leading to 
a high absorption (e >105 M-I cm-l), and fluorescence in the visible region of the 
compounds. 
The chromophoric region of the cyclic tetrapyrroles is based on the porphin ring 
(Fig. 1.1). The light absorption properties of the tetrapyrrole can be modified by metal 
ligands attached to the central region of the molecule and by side groups attached to the 
outside of the ring. Four medically relevant classes of tetrapyrroles which absorb in the 
far red region of the visible spectrum are: the porphyrins; the chlorins; the 
bacteriochlorins; and the phthalocyanines (Fig. 1.2). The chlorins can be defined as 
dihydroporphyrins due to the saturation of a pyrrole. The phthalocyanines are also 
referred to as azaporphyrins. The rich colours of the cyclic tetrapyrroles also have led to 
their commercial application as pigments and dyes in paints for example. 
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Figure 1.1. The space filled molecular model of the porphin ring viewed from two 
different orientations, and the chemical structure showing the planar shape of tetrapyrroles 
(d= 7.3 A; surface= 49 A"). 
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Figure 1.2. Representative molecules from four of the tetrapyrrole classes which have 
potential medical applications: Protoporphyrin = porphyrin; chlorophyll a = chlorin; 
bacteriochlorophyll a = bacteriochlorin; tetrasulfonated aluminum phthalocyanine = 
phthalocyanine. 
4 
A photon, once absorbed by a tetrapyrrole,can have several fates. The large 
conjugated double bond ring structure of these molecules permits an absorbed photon to 
be either emitted at a longer wavelength as fluorescence, or passed to another molecule 
as energy, resulting in photosensitization. The surroundings of the tetrapyrrole molecule 
can affect the choice of fates of an absorbed photon. For example, if an acceptor 
molecule such as oxygen is in proximity to the tetrapyrrole, then the photon energy could 
be passed to the oxygen; however if there is no acceptor molecule in proximity, then the 
photon energy may be re-emitted from the tetrapyrrole as fluorescence . 
The cyclic tetrapyrroles have a diverse collection of roles in nature. Sorne notable 
examples of such functions are: i) chlorophyll, a chlorin or dihydroporphyrin which is 
responsible for the photosynthesis in plants; ii) heme, an iron metalloporphyrin which is 
involved in oxygen transport of blood; iii) cytochrome, another iron metalloporphyrin 
which is involved in several energy transfer functions of the respiratory electron transport 
pathway; and iv) the corrin ring of the vitamin B 12' a cobalt metalloporphyrin which acts 
as a coenzyme in several enzymatic processes. The molecular structures of the 
tetrapyrroles involved in these examples are illustrated in Figure l.3 . Sorne cyclic 
tetrapyrroles also have a potential use in medical applications such as disease diagnostics 
and cell killing due to their fluorescence and photosensitization properties. 
1.2 Use of cyclic tetrapyrroles in medicine 
The application of light in either the diagnosis or treatment of disease is called 
photomedicine. Modem photomedicine can be separated into two fields, i) phototherapy 
and ii) photochemotherapy. In phototherapy, light alone is applied, which is absorbed by 
endogenous chromophore molecules, resulting in a photochemical response. In 
photochemotherapy, exogenous chromophore molecules such as the cyclic tetrapyrroles 
are administered prior to the illumination. The administered exogenous molecules will 
absorb light leading to the photochernical response through photosensitization. In sorne 
photochernotherapy cases, oxygen is required as the energy acceptor. Then, the 
photochernical reaction is called photodynarnic. 
Chlorophyll a 
H ... 
-...../ 0 . 
\ Il NU O-P-~H< 1 d- N '-
B 2 0 l CH OH 2 
5 
HOOC Hemeo 
HOOC CO OH 
Protoporphyrin IX 
Figure l.3 . Molecular structures of sorne common natural tetrapyrroles: chlorophyll a; 
heme a, the tetrapyrrole unit of the cytochromes; vitamin B12' which contains the corrin 
ring; and protoporphyrin IX the precursor hemoglobin. 
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Photomedicine has been practiced in sorne form for over thirty centuries in India, 
China, and Egypt. Modern scientific investigation into photomedicine and its mechanisms 
began in the early 1900's. Several skin disorders such as pityriasis, versicolour, and 
psoriasis vulgaris were treated in the early 1900's by applying exogenous photosensitizing 
dyes and light (von Tappeiner and Jesionek, 1903). The selective response of diseased 
tissue was observed in such early photomedicine treatments; the normal tissue surrounding 
the diseased area was unaffected by the photosensitization reaction and the light induced 
photosensitization was selective to wounded and/or rapidly proliferating tissues. 
The brilliant red fluorescence of cyclic tetrapyrrole dyes, coupled with their 
selective retenti on within rapidly proliferating tissues such as tumours, was shown to 
provide a useful diagnostic tool for cancer. Tumours in animaIs emitted a bright red 
fluorescence when irradiated with blue light after the exogenous porphyrin dye 
hematoporphyrin (HPIX) was administered to the animaIs (Rassmussen-Taxdal et al., 
1955). Sorne years later Lipson et al. (1961) confirmed that an exogenous porphyrin dye 
that had been administered to animaIs and/or human patients could selectively localize in 
tumour tissue and be used for diagnosis of the tumours due to the red fluorescence of the 
dye when illuminated with intense blue light. 
By combining the selective retention and photosensitization characteristics of 
tetrapyrrole dyes it was proposed that these dyes could be used to kill cells and destroy 
tumour tissue. The treatment by photosensitization of lesions had been known for many 
years, but the application of these properties of dyes to cancer treatment was a new 
concept. Damage to tumour cells was observed when those cells were irradiated with 
visible light after prior administration of the dye HPIX (Diamond et al. , 1972). This 
treatment for cancer known as photodynamic therapy (PDT) can be described as the 
selective retention by tumour tissue of a photosensitizer which will generate reactive 
compounds by photosensitization and those reactive compounds will undergo chemical 
reactions with biomolecules leading to cell death (Fig. 1.4). 
With the establishment of PDT, research was initiated in an attempt to improve 
the photosensitizer properties relevant to photodynamic therapy. As a result of these 
investigations many new and modified forms of photosensitizing dyes continue to be 
Injection of 
photosensitizer 
Selective 
retention 
in the tumour 
........ 
........ 
24-48 hrs 
after injection 
Destruction of 
the tumour 
with light 
........ 
........ 
Figure 1.4 Generalized scheme ofphotodynamic therapy treatment using a photosensitizer injected IV. --...) 
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synthesized in order to improve the PDT response of tumours. A brief survey of sorne 
tetrapyrrole photosensitizer dyes is warranted since many have a potential use as PDT 
agents. 
The first tetrapyrrole based dye used as a light activated anti-tumour agent was 
hematoporphyrin derivative (HpD) (Lipson et al., 1961). HpD is a water soluble 
formulation derived from the porphyrin hematoporphyrin (HPIX) (Lipson et al., 1961). 
HpD has been shown to contain several different components (Bonnett and Berenbaum, 
1989). The active anti-tumour components of HpD were further isolated and purified, and 
the purified active anti-tumour composition of HpD is now called Photofrin. Photofrin 
was found to contain a polymeric mixture of dihematoporphyrins and oligomers (Kessel 
and Cheng, 1985; van Lier, 1988). A commercial preparation of the original Photofrin 
is called Photofrin porfimer sodium® or Photofrin n ® (PFII) (Quadra Logic Technology 
Inc., Vancouver, B.e., Canada). Photofrin n ® has improved light activated anti-tumour 
properties as compared to the original Photofrin. Other research groups have also 
synthesized a variety of tetrapyrrole based dyes in an attempt to find compounds with 
improved anti-tumour properties as compared to PFII. The primary aims when 
synthesizing the new dyes, were to improve the dye properties of tumour selectivity (for 
example via increased hydrophobicity) and to increase the far red absorbance in order to 
take advantage of the high tissue transmission of far red light. These new far red 
absorbing dyes have been categorized as "second generation photosensitizers". Sorne of 
these, which have a potential use for PDT, are summarized in Table 1.1. 
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Table 1.1: Summary of sorne of the more promlsmg second generation PDT 
photosensitizers. 
Photosensitizer Hydrophobicity J..",ax (nm) a 
NPe6 hydrophilic 660 
AISPc hydrophilic 670 
BPD-MA hydrophobie 690 
SnET2 hydrophobie 650 
Pheophorbides (HEDP) hydrophobie 660 
ALA hydrophilic 640 b 
Cationic dyes (CPS) hydrophilic 600-900 c 
(a) The approximate location of the longest absorption wavelength relevant to PDT; (b) ALA is converted 
to protoporphyrin IX within tissues; (c) Many different CPS dyes have been suggested for PDT with 
absorption ranging from 600-900 nm. Abbreviations : NPe6= Mono-L-aspartyl chlorin e6, AISPc = 
Sulfonated aluminum phthalocyanine, BPD-MA= Benzoporphyrin derivative monoacid ring A, SnET2= Tin 
etiopurpurin, ALA.= Aminolevulinic acid (from Grossweiner, 1994). 
Of the many potential exogenous tetrapyrrole photosensitizers currently under 
investigation for use in PDT, PFII, mono-L-aspartyl chlorin e6 (NPe6), benzoporphyrin 
derivative monoacid ring A (BPD-MA), and tin etiopurpurin, are currently in various 
stages of clinical trials (Spikes and Bommer, 1993; Dougherty, 1993). The PDT 
photosensitizer formulation PFII has been approved for clinical use in bladder 
malignancies (Marcus, 1992; Dougherty, 1993). As other potential PDT photosensitizers 
undergo clinical trials, it can be expected that more of these will be approved for clinical 
use. 
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Chapter 2 Background 
2.1 Modes of action in PDT 
From an operational viewpoint, PDT can be subdivided into four phases: i) drug 
administration, ii) distribution into tissues, iii) photosensitization, and iv) biochemical 
reactions. These phases are discussed individuaIly in the foIlowing subsections. 
2.1.1 Drug administration 
There are three major factors that need to be optimized for successful drug 
administration : i) the administration route by which the dye is introduced into the body; 
ii) the solvent mixture (solvent formulation) used to dissolve the photosensitizer dye; and 
iii) the blood component (blood fraction) which transports the dye to the various tissue 
sites. 
The six possible administration routes for PDT photosensitizing dyes are: i) 
intravenous (IV); ii) intraperitoneal (IP); iii) intradermal (ID); iv) intratumoural (IT); v) 
oral; and vi) topical. The first two (intravenous and intraperitoneal) are the most 
frequently used of aIl these possible administration routes. The four other possible routes 
are of limited use mainly due to the poor membrane transport of large molecules such as 
the tetrapyrroles and the potentialleakage of the dye from the administered site into other 
normal tissues. Wh en the dye is injected IV or IP, the photosensitizer must enter the 
circulatory system in order to travel to specific tissues. Two routes of administration 
whereby the drug may not need to pass through the circulatory system are intratumoural 
and topical (Kostron et al., 1985; Hebeda et al. , 1995). Other administration methods for 
PDT dyes, such as intratumoural injection (IT), may in sorne cases provide better dye 
selectivity for the tumour tissue, as suggested by Hebeda et al. (1995) who used the IT 
injection into brain neoplasia. The IT injection of a PDT drug directly into the brain 
bypasses the transport inhibition across the brain's blood barrier. Leakage of the dye from 
the intratumoural injection site into other normal brain tissues was a major difficulty 
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encountered with that application method (Hebeda et al. , 1995). The second exception 
to using the blood for transporting a compound to the tumour is the topical administration 
of 5-aminolevulinic acid (ALA) to the tumour site (Kennedy and Pottier, 1992). ALA can 
penetrate the skin and diffuse directly into the tumour due to its smaIl size and water 
solubility. Once ALA is assimilated by tumour cells it is metabolized into the 
endogenous photosensitizer protoporphyrin IX. 
The dye can bind to different blood fractions depending on the solvent 
formulation and its hydrophobicity. For example, the dye ketochlorin (C8KC) binds to 
the low density lipoprotein (LDL), instead of the albumin blood fraction, when the more 
hydrophobic Cremophor EL (CRM) rather than the less hydrophobic Tween 80 (TX80) 
is used as the solvent formulation (Woodbum et al. , 1994). The hydrophobicity of the 
solvent formulation carrying the dye can also modify the dye's concentration in tissues 
as weIl as its tissue distribution (Reddi et al. , 1990; Gurinovich et al. , 1992; Henderson 
and Dougherty, 1992; Jori, 1992; Kessel and Morgan, 1993 ; Obochi et al. , 1993; 
Rosenberger and Margalit, 1993 ; and Woodbum et al. , 1994). For example the 
concentration of the dye ketochlorin (C8KC) increased in aU tissues when Cremophor EL 
solvent formulation was used instead of the solvent formulation Tween 80 (Woodbum et 
al. , 1994). AIso, the ratio of dye concentration in tumour to muscle increased from 3.3 
to 5.5 for the photosensitizer ZnPc when LDL instead of liposomes was used as a solvent 
formulation (Reddi et al. , 1990). 
For PDT the importance of photosensitizer binding to the LDL is associated with 
the large number of LDL receptor sites on neoplastic ceUs. Those LDL receptor sites 
permit the LDL-bound dye to be incorporated into neoplastic ceUs by endocytosis. Hence 
the PDT dye is often transported more efficiently to the tumour when the dye solvent 
formulation contains blood proteins. The dye selectivity for tumour tissues and the dye 
concentration in tumour tissue wiU often increase when LDL is part of the solvent 
formulation or when the solvent formulation enhances the photosensitizer binding to LDL 
present in the blood (Jo ri , 1992). For example the photosensitizer (HpD) concentration 
increased in ceUs when LDL rather than high density lipoprotein (HDL) or human serum 
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albumin (HSA) was included in the drug-solvent formulation (Rosenberger and Margalit, 
1993). The degree of hydrophobicity of a photosensitizer affects its binding to the LDL 
protein fraction (Moan and Berg, 1992). For example the water soluble dye chlorin e6 
binds to the LDL when that dye is rendered more hydrophobic by the addition of an 
amide to that dye (Gurinovich et al. , 1992). Thus, the degree of hydrophobicity of a dye 
or the solvent formulation containing a dye can increase the dye's binding to LDL and 
increase the tumour selectivity of the dye. 
2.1.2 Kinetics of tissue distribution (pharmacokinetics) of photosensitizers 
The pharmacokinetic properties of an anti-tumour photosensitizer can be examined 
in three parts: i) the clearance of the dye from a tissue; ii) the selective distribution of the 
dye in different tissues; and iii) the distribution of the dye within subcellular organelles 
of a cell . 
The clearance curve of a drug is derived from the drug's concentration while the 
drug moves through the body to be eventually metabolized or cleared. A triexponential 
equation mathematically describes the clearance curves of most tetrapyrrole 
photosensitizers from several tissues (Henderson and Bellnier, 1989). For example, 
radiolabeled Photofrin n® (PFII) has three elimination half lives at 4 h, 9 days, and 36 
days as it is cleared from the serum of DBA mice (Henderson and Bellnier, 1989). PDT 
treatment can be coordinated with photosensitizer peak concentration in the body by 
knowing the clearance curves of the dye in the relevant tissues. The time at which the 
peak concentration of different photosensitizers is observed can be quite different (2 to 
60 min for NPe6, 3h for BPD-MA, and 5 to 10 h for PFII) (Grossweiner, 1994). 
The selective retention of an anti-tumour dye by tissues can be determined from 
its clearance rate from those tissues relative to others (Fig. 2.1). The tissue distribution 
of a dye may not remain constant while the dye passes through the body, due to different 
clearance rates from different tissues. Thus, the tissue distribution is time dependent. For 
example, at 1h post injection, the NPe6 concentrations in the tumour and muscle were 
respectively 3.81 Ilg gol and 0.86 Ilg gol, but after 10 h these corresponding values were 
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l.49 Ilg g-! and 0.11 Ilg g-! (Gomer and Ferrario, 1990). Thus, while the absolute drug 
concentration in the tumour only diminished by half, the tumour to muscle ratio actually 
increase threefold. The clearance curve and the peak concentration of a dye in the tumour 
are two crucial points used by clinicians to determine the best treatment time for PDT. 
The optimum PDT treatment time normally occurs when the dye concentration is 
highest in malignant tissue and lowest in the surrounding normal tissues. The ratio of the 
dye concentration in the malignant tissue to the surrounding normal tissue as a function 
of time is used to estimate the treatment time. This concentration ratio is often referred 
to as "the tumour to normal muscle" (TIM) ratio, since the surrounding tissue of a tumour 
is frequently muscle. A photosensitizer is considered to have a high tumour selectivity 
when its TIM ratio is large. Two examples of dyes that have high tumour selectivity and 
a high TIM ratio are BPD-MA (TIM ratio=19.2) (Richter et al., 1993), and AIS2Pc (TIM 
ratio=9.8) (Peng et al., 1993). The pharmacokinetics, tissue distribution, and TIM ratios 
of sorne second generation photosensitizers are summarized in Table 2.1. 
The pharmacokinetics and tissue distribution of tetrapyrrole photosensitizers can 
vary between different animal breeds or different tumour types within the same animal . 
For example, the chlorin e6 peak concentration varied from 2.5 to 9.5 Ilg g-! in different 
tumour types within the same animaIs (wistar rats) (Kostenich et al., 1993). The TIM 
ratio for chlorin e6 also peaked at different values and times in different tumours within 
the same animaIs (Kostenich et al. , 1994). For example, the TIM ratio peaked at 18 h at 
a value of 8.8 in the Ml tumours and at 12 h at a value of 6.0 in the tumour type 45 
(Table 2.1). Thus, the pharmacokinetics and tissue distribution of a dye from one animal 
model or tumour type may not be applicable to another animal or tumour type, and the 
optimum PDT treatment time can also vary between tumour or animal type, since the 
pharmacokinetics and tissue distribution of the dye within the body are used to estimate 
the PDT treatment time. It is thus obvious that pharmacokinetics data obtained from 
animal models may not readily conform to human pharmacokinetics data. 
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Figure 2.1. Clearance curves for radiolabeled Photofrin II in DBA/2 Ha mice for various 
tissues. AnimaIs received 5 mg kg-lof 14C Photofrin II IP and were killed at the indicated 
intervals. Each point is the average of values from 3 to 6 animaIs, which differed by less 
than 30%. Concentrations in the liver C") , kidney (0 ), spleen (.), lung (t..), heart (e), skin 
contralateral to the tumour (D), muscle ('~), and SMT-F tumour ( ....... ) were calculated as 
if aIl radioactivity was accounted for by 14C Photofrin II. The letters indicate 24 h points 
for the following organs: A, adrenal glands; P, pancreas; S, stomach; F, femur; U, urinary 
bladder; B, brain. (from Henderson and Bellnier, 1989). 
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Table 2.1: Surnrnary of recent pharrnacokinetics data for of sorne second generation 
photosensitizers adrninistered by IV or IP. 
Sensitizer Dose Tissue Tissue Time TIM T/S Reference 
(mg kg-l) conc Ch) Ratio Ratio 
(flg g-l) 
SnET2 1.5 Tumour 0.2 24 l.0 Kessel and 
Skin 0.2 Morgan, 
Liver 0.8 1993 
Plasma 0.7 
Bchlorin 5 Tumour 0.94 4 4.5 Kessel et 
CA-6E Skin 0.21 al., 1993 
Plasma 0.4 
Ketochlorin 5 Tumour 6.69±1.25 24 4.0 2.9 Woodburn 
C8KC Skin 2.27±0.12 et al., 
(CRM Muscle l.69±0.16 1994 
formulation) Liver 22.45±2.5 
Plasma 9.97±2.14 
Ketochlorin 5 Tumour 3.5±0.43 24 4.2 2.4 Woodburn 
C8KC Skin l.46±0.18 et al. , 
(TW80 Muscle 0.84±0.05 1994 
formulation) Liver 24.77±0.4 
Plasma 4.72±0.60 
ChI orin e6 10 Tumour (MI) 4.4±0.4 18 8.8 Kostenich 
Muscle 0.5±0.1 et al. , 
Liver 2.0±0.3 1994 
Blood 12.0±0.6 
Chlorin e6 10 Tumour (45) 3.6±0.3 12 6.0 Kostenich 
Muscle 0.6±0.2 et al., 
Liver 2.6±0.2 1994 
Blood 14.2±0.7 
Bchlorin a 10 0.5- 2.4 Schuitmak 
24 er et al., 
1993 
MPH 5.8 Tumour 20.4 Mayhewet 
Liver 25 .7 al., 
Blood 14.8 1993 
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Sensitizer Dose Tissue Tissue Time TIM T/S Reference 
(mg kg-1) conc (h) Ratio Ratio 
(flg g-l) 
Chlorin e6 10 Tumour(SM-1) 4.4±0.4 24 Kostenich 
Tumour(S45) 2.5±0.6 24 et al. , 
Tumour(pC-1) 7.4±0.1 24 1993 
Tumour(pLS) 3.7±0.1 24 
Blood 9.5±0.7 24 
Tumour(SM-1 ) 7.6±0.1 0.25 
Tumour(S45) 6.7±0.9 0.25 
Tumour(pC-1 ) 9.1±0.2 0.25 
Tumour(pLS) 10.8±0.8 0.25 
Blood 35±1.7 0.25 
mPheo a 10 Tumour 6.3±0.7 Kessel and 
mPheo b Tumour 5.7±0.6 Smith, 
1989 
Chloro Al 10 Fibrosarcoma 24-48 2 Chan et 
SPc M5076 Sarcoma 4 al., 
Colon 26 7 1988 
Si NPc Tumour 0.58±0.13 48 l.l6 Biolo et 
Skin 0.50±0.08 al. , 
Liver 9.78±1.25 1994 
Serum 0.21±0.11 
Zn NPc .25 Tumour 1.5±0.70 20 2.5 Shopova et 
Skin 0.60±0.20 al., 
Liver l.20±0.50 1994 
PF II 0.2 Jori, 1992 
NPe6 5 Tumour 3.81±1.64 4.43 1.04 Gomer and 
Skin 3.67±0.66 Ferrario, 
Muscle 0.86±O.28 1990 
Liver 16.92±4.9 
Plasma 12.91±3.0 
BPD-MA 4 Tumour l.7±0.30 3 5.9 Richter et 
0.8±0.20 24 19.2 al., 1993 
Ammonium 20 Tumour 100% 10 3.0 Kawabe et 
Salts Skin 33% al., 
of PP Muscle 10% 1991 
Liver 23 .3% 
Al S2PC 10 Tumour 7 48 9.8 2.3 Peng et 
Skin 3.5 al. , 
Muscle 1993 
Liver 40 
Sensitizer 
isoBosinc 
Al SPc 
HPPH 
Zn NPc 
Al SPc 
Chlorin e6 
EDA 
Zn Pc 
Zn Pc 
(liposomes) 
Zn Pc 
(LDL) 
0.25 
20 
0.3 
5 
10 
10 
0.5 
0.12 
0.12 
Tissue 
Tumour 
Skin 
Muscle 
Serum 
Tumour 
Skin 
Muscle 
Tumour 
Skin 
Plasma 
Tumour 
Muscle 
Liver 
Colon 
Pancreas 
Brain 
Tumour 
Muscle 
Liver 
Tumour 
Muscle 
Liver 
Tumour 
Muscle 
Liver 
Tumour 
Muscle 
Liver 
Tumour 
Muscle 
Liver 
Tissue Time 
conc (h) 
(Ilg g-l) 
0.61±0.06 24 
0.42±0.l3 
0.07±0.01 
1.17±0.08 
14 
4.7 
3.2 
3 
0 .5 
9 
0.7 
0.50 
0.65 
48 
24-48 
24 
16 
5 
20 
40 
3 
10 
0.75 
0.1 
.5 
0.3 
0.1 
0.3 
0.55 
0.1 
0.3 
36 
12 
24 
6 
18 
24 
24 
24 
TIM 
Ratio 
8.7 
4.4 
1.4 
2 (TIN) 
3 (TIN) 
28 (TIN) 
3.2 
l3 .3 
7.5 
3 
5.5 
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T IS Reference 
Ratio 
l.5 Zuk et al., 
1994 
3.0 
6 .0 
Chen et 
al., 
1993 
Bellnier et 
al., 1993 
Wohrle et 
al., 1993 
Tra1au et 
al., 1987 
Gurinovich 
et al., 
1992 
Reddi et 
al., 1987 
Reddi et 
al., 1990 
Abbreviations: TIM= Drug concentration ratio of the tumour to muscle ; TIN= Drug concentration ratio of 
tumour to normal tissue; T/S= Drug concentration ratio of tumour to skin; ET2= Etiopurpurin; Bch10rin= 
Bacterioch10rin; CRM= Cremophor EL formulation; TW80= Tween 80 formulation; MPH= Methyl 
pheophorbide a-hexyl-ether; mPheo= Methylpheophorbide a; Ch10ro Al SPc= Chloro aluminum sulfonated 
phthalocyanine; NPc= Naphthalocyanine; PF II= Photofrin II®; NPe6= Mono-L-aspartyl chlorin e6; BPD-
MA= Benzoporphyrin derivative monoacid ring A S2PC= Disulfonated phthalocyanine; isoBosinc= Bis(di-
isobutyloctadecylsiloxy)silicon naphthalocyanine; SPc= Sulfonated phthalocyanine; HPPH= 2-[ 1-
Hexyloxyethyl]-2-devinyl pyropheophorbide a; LDL= Low density lipoprotein; EDA= Chlorin e6 
ethy1enediamide. 
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Skin photosensitivity is a concem in PDT treatment of human patients, due to the 
fact that the photosensitizer may linger in the skin for sorne time after treatment. Thus, 
a higher selectivity for tumours, less selectivity for skin, and faster skin clearance would 
be desirable characteristics for improved PDT photosensitizers. The skin photosensitivity 
can occur for qui te a long time after PDT treatment. For example, 2 months after 
administration PFn was still detected (Henderson and Dougherty, 1992). The duration 
of skin photosensitivity is decreased when using sorne of the new photosensitizers 
developed for PDT. For example, skin photosensitivity was reduced to 2 weeks when 
using the dye AIPcSn (Tralau et al., 1989), 5 days for bacterial chlorophyll a (bChl a) 
(Henderson et al. , 1991), and 24 h for the new photosensitizer NPe6 (Roberts et al. , 
1989). Sorne of these new dyes can be easily photodegraded, and this assists in clearing 
them from the skin (Henderson and Dougherty, 1992). The photodegradation of the 
sensitizer by normal ambient light may partly explain the short duration of skin 
photosensitivity observed with sorne of these new photosensitizers (Henderson and 
Dougherty, 1992). 
Dye selective retenti on can occur within regions of a given tissue as weIl as 
between tissues. The vascular regions of a tumour will often selectively retain 
photosensitizer dyes (Henderson and Dougherty, 1992). When the photosensitizer 
concentration in proximity to the vascular network of the tumour is high relative to the 
other tumour regions, vascular damage is also apparent during PDT treatment (Henderson 
and Dougherty, 1992; Korbelik and Krosl, 1994). Damage to the vascular system of the 
tumour interrupts the blood supply to the tumour, thereby starving it of nutrients and 
oxygen. This mechanism has been proposed for tumour killing by PDT (Marcus, 1992). 
Tetrapyrrole dyes can selectively localize into various organelles within cells. 
Most of the hydrophobic dyes bind to membrane-ri ch organelles such as the mitochondria 
(Ricchelli et al., 1993), the lysosomes (Gèze et al. , 1993), and the golgi apparatus (Moser 
et al., 1992), whereas the hydrophilic dyes bind to aqueous non-membrane cytoplasmic 
sites, such as proteins (Kessel and Smith, 1989). Thus the sub-cellular localization of a 
tetrapyrrole photosensitizer can be affected by its hydrophobicity or lipophilicity, which 
may affect the location of sub-cellular damage. 
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2.1.3 Light penetration into tissue 
The spectral properties of the activating light must be matched to the absorption 
of the photosensitizing dye, and must be able to penetrate into the tissue for it to interact 
with the photosensitizer that is located in that tissue. It is desirable during PDT that the 
photosensitization process occur only in the tumour tissue, but in sorne cases the 
activating light may also have to penetrate through other tissues in order to reach the 
tumour. The absorption of aIl the tissues in the light path can change the light intensity 
and spectral properties, which may thus not correspond to those of the irradiation source. 
Light scattering and absorption by endogenous chromophores are the principal properties 
of tissues which are responsible for modifying light penetration. The typical light 
transmission curve that results from these tissue properties is shown in Fig. 2.2. The light 
transmission through typical tissues slowly increases with increasing wavelength to level 
off at about 700 nm. Thus the preferred wavelengths of light for PDT activation are these 
higher wavelengths (650-900 nm), due to the higher light transmission. This requires a 
PDT dye to have an absorption band in this region for the best photosensitization. 
Quantification of the amount of photoactivating light present at the treatment site 
would provide the most precise method of determining actual light dosimetry. Frequently 
this is not possible or practical. Tissue model systems permit the light properties within 
the tissues to be estimated (Wan et al. , 1981 ; Grossweiner, 1987, 1994; and Patterson et 
al., 1991a, 1991b). The light measured at the illumination source can be corrected using 
these model systems in order to estimate the light properties within the tissues. 
Alternately, light monitoring devices that permit simultaneous in situ measurements during 
PDT treatment are in continuaI development (Stamp and Williams, 1991 ; Sroka et al. , 
1993; and Grossweiner, 1994). 
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Figure 2.2. A generalized light transmittance curve through tissues (note the log scale). 
The absorption peak of the common classes of PDT drug is overlaid on the tissue light 
transmission curve. (from Bonnett and Berenbaum, 1989). 
Strongly absorbing photosensitizers in the upper tissue layers can shade or screen 
the light penetration into the underlying deeper tissues. A significant percentage of the 
photons from a light source can be absorbed by photosensitizers early in the light path 
such that the underlying tissue layers are effectively shaded. This screening, or optical 
shading of deep-Iying tissues, has been observed with sorne of the far red PDT 
photosensitizers with high molar extinction coefficient, such as the phthalocyanines 
(Henderson, 1989). For example, the transmittance of 680 nm light was reduced by 50% 
through tissue containing the dye Ga phthalocyanine (GaPc) compared to that same tissue 
without GaPc (Henderson, 1989), while the transmirtance of 630 nm light (which is not 
absorbed by GaPc) in that same tissue was not reduced, confirming that the light 
attenuation resulted from the GaPc absorption. The shading of underlying tissues by 
strongly absorbing dyes can limit the available light needed for PDT photosensitization 
, 
., 
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ln deep-Iying tissues, resulting in decreased PDT actlvlty ln those deeper tissues 
(Dougherty and Porter, 1990). Such optical shading could partly explain why only a 
threefold increase in PDT effectiveness was observed with phthalocyanines compared to 
HpD, even though phthalocyanines absorb 20 times more than HpD (Jori et al. , 1984). 
A proposed solution to overcome optical shading is to maintain the photosensitizer 
concentration in tissues at a level where the effect of shading is minimized (Dougherty 
and Porter, 1990). 
Light penetration can also be reduced by endogenous melanin pigments present 
in tissues in a manner similar to the optical shading by strongly absorbing dyes. Melanin 
is a yellowish brown or black pigment normally found in the skin. Melanin formation 
is light stimulated such that increased light exposure accelerates the formation of melanin 
and its migration into the upper skin layers. The main purpose of melanin in the upper 
skin layers is to absorb harmful electromagnetic radiation, thus preventing the radiation 
from penetrating into the skin. In other words, melanin acts as an endogenous sun screen 
absorbing excessive UV light from sun light. The melanin absorption is particularly high 
for UV light and gradually decreases to near zero by 900 nm (Epstein, 1989). Under 
sorne conditions and in sorne skin types the amount of melanin pigments in the skin can 
be considerably higher than normal for caucasian type skin, which results in a larger 
artenuation of light penetration through the skin. PDT using any visible light absorbing 
dye may be affected significantly due to the melanin absorption at visible wavelengths 
typically used for photosensitization. 
One type of skin cancer, pigmented melanoma, contains high concentrations of 
melanin, which can result in significantly reduced PDT effectiveness. Treatment of 
pigmented melanomas by PDT may be improved by using far red absorbing dyes sin ce 
those wavelengths are less affected by melanin absorption. Sorne of the new second 
generation photosensitizers meet the necessary requirement of high molar extinction 
coefficient in the far red region of the visible spectrum (780-800 nm). A preclinical PDT 
treatment study of a pigmented melanoma (B 16) in mice using the anti-tumour 
photosensitizer Si(IV)-Naphthalocyanine (SiNc) has been shown to pro duce partial results 
(Biolo et al. , 1994). 
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2.1.4 Photosensitization by tetrapyn-oles used in PDT 
Photodynamic photosensitization involves the transfer of excitation energy from 
the dye to molecular oxygen. Typically, it is the dye triplet state which transfers energy 
to oxygen, due to the long lifetime of the triplet, which permits it to interact with oxygen. 
The triplet quantum yield (<:Dr) is a measure of the probability that a light activated dye 
molecule will form the excited triplet state. A large <:Dr implies that more triplet dye 
molecules can be pro duce d, leading to a potentially higher photosensitization efficiency. 
There are two possible photochemical mechanisms by which reactive oxygen 
species can be generated, each involving the interaction of the triplet photosensitizer 
molecule with ground state 0 2' These two photochemical schemes are termed type 1 (Eq 
1 a and 1 b) and type 2 (Eq 2a and 2b). The oxygen becomes a radical ion in the type 1 
reaction scheme due to electron transfer from the photosensitizer triplet. Singlet oxygen 
C02) is generated in the type 2 reaction scheme, due to the energy transfer from the triplet 
photosensitizer to the triplet ground state oxygen. The photosensitizer molecule returns 
to the ground state in the type 2 reaction scheme after the energy has been transferred to 
oxygen; thus, that dye molecule can absorb another photon and repeat the reaction. 
Conversely, a type 1 reaction may result in destruction of the photosensitizing molecule . 
Type 1: 
Type 2: 
. + 
peT]) + Subs ~ P + Subs (la) 
+ 
peT]) + O2 ~ P + O2 (lb) 
peT]) + 30 2 ~ peSo) + ]°2 * (2a) 
]0 2* + Subs ~ Photo-oxidation (2b) 
Reaction scheme for type 1 and type 2 photosensitization with oxygen. 
P= Photosensitizer; T= Triplet; Subs= Substrates; So= Ground state singlet. 
23 
The main reactions involved in PDT photosensitization are believed to be type 2 
(van Lier and Spikes, 1989; Patterson et al. , 1990), but type 1 reactions cannot be 
completely excluded (Persad et al. , 1983 ; Hadjur et al. , 1995). The type 2 reaction 
scheme can be virtually catalytic, since the photosensitizer returns to the ground state after 
it has transferred the photon energy to oxygen, which implies that a single photosensitizer 
molecule may pro duce many 10 2 molecules. A substantial biological effect can result 
from rather low photosensitizer concentration, due to this catalytic cycle of the type 2 
reaction scheme. 
For oxygen photosensitization by a dye, the dye triplet state must possess 
sufficient energy to permit excitation of the ground state oxygen triplet to the singlet 
excited state C02)' A tetrapyrrole dye requires - 150 kJ mol-l of excitation energy « 800 
nm light) due to a loss of 50-60 kJ mol-l of that energy during singlet to triplet inter-
system crossing of the dye (van Lier and Spikes, 1989; Grossweiner, 1994). Photons of 
longer wavelengths than 800 nm could be used to excite a given dye still permitting 10 2 
formation, if the dye's energy loss during the intersystem crossing between the singlet and 
triplet excited states could be reduced. 
The quantum yield of singlet oxygen production (<I>À) from photosensitization by 
a dye is often used to estimate PDT effectiveness of that dye (Grossweiner, 1994). The 
<I>À for the dye is usually measured in solvent or organized lipid systems in vitro, rather 
than in vivo . This is due to an inability to detect 10 2 in vivo . A single case of 10 2 
detection in vivo has been reported (Parker, 1987). This result has not been repeated in 
other laboratories, in spite of numerous attempts. Patterson et al. (1990) have determined 
that the lifetime of 102 in vivo is less than 5 ~s, which is shorter than the detection time 
constant of current instrumentation. 
The quantum yield of 10 2 and photosensitizer triplet (TI) properties can be used 
in preliminary evaluation of any new potential PDT photosensitizer. The PDT activity 
of a dye generally increases as these quantum yields increase. A detailed review of 
values of <I>À, <I>TI, and other physical properties of many potential photosensitizers has 
been given by McGarvey and Truscott (1990) . Table 2.2 documents sorne recent data on 
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Table 2.2: Summary of recent photophysical values from sorne potential PDT 
photosensitizers. 
Sensitizer Singlet Triplet Triplet 102 Solvent Reference 
Lifetime Lifetime <DT <Dt. 
(ns) (fls) 
CA-6E 3.75 ethanol Kessel et al. , 
1993 
bChl c 200-250 .6 1 acetone Krasnovsky 
ChI a .63 etaI. , 1993 
bChld 200.220 .55 
bPheophytin c .77 
bPheophytin d 200-215 .75 
bPheophorbide d .75 
TPP 350-370 .65 
Azaporphyrin .65 toluene Schiwon 
et al., 1994 
ChI derivatives 190 .37 .3 9 benzene Fiedor et al. , 
330 .29 .30 D20 1993 
NPe6 300 HP Spikes and 
.77 DP Bommer, 
1993 
Pheo a 1.0 0.60 EtOH Krasnovsky 
0.6 0.74 di ethyl ether etai., 1990 
1.1 H2O/triton 
0.50 Dp/triton 
ChI a 0.60 EtOH Krasnovsky 
1.60 di ethy 1 ether et al., 1990 
0.57 CC14 
Pheophytin a 1.1 0.60 EtOH Krasnovsky 
0.70 0.70 di ethy 1 ether et al. , 1990 
1.0 Hp/triton 
0.70 D2O/triton 
Chlorin e6 5.3 EtOH Adam et al., 
Pheo a 6.1 1987 
HP 12 .0 Roeder and 
Wabnitz, 
1987 
bChl c 2.6 MeOH Brune et al. , 
6.5 CH2CI/MeOH 1988 
7.6 DMSO 
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Sensitizer Singlet Triplet Triplet 10 2 Solvent Reference 
Lifetime Lifetime <DT <Dt. 
(ns) (ilS) 
HpD .215 liposomes Gross et al. , 
PFII .191 1993 
MTBP .019-
ZnPc(OH4) .023 
0.005 
BPD-MA 5.2 25 methanol Aveline et 
0.68 0.78 benzene al., 1994 
Chalcogenapyry lium .0004- methanol Detty and 
.12 Merkel, 
1990 
Pery lenequinonoid .07-.83 benzene Diwu and 
Lown, 1993 
PFII (mono) 0.60 0.30 orgamc Jori, 1992 
PFII (aggreg) 0.20 0.10 solve nt 
bChlorin 0.54 0.20 or 
Zn Pc 0.67 0.53 organized 
Zn Pc Deriv's 0.46- 0.35- systems 
Cu Pc 0.59 0.45 (eg 
Si (IV) NPc 0.95 0.00 liposomes) 
0.39 0.19 
H2 TNP 0.47 DMF Roitman et 
0.24 ethanol al. , 1994 
0.375 pyridine 
Zn TNP 0.6 DMF 
0.38 ethanol 
0.76 pyridine 
Porphyrin c 8.0 l.0 aqueous Ghiggino et 
Zn Pc 2.0 0.73 buffer al., 1988 
HpD 0.54 
Zn NPc 110-330 0.20 .135- DMSO Wohrle et 
.164 al. , 1993 
Abbreviations: CA-6E= Bacteriochlorin derivative ; bChl= Bacteriochlorophyll; Chl= Chlorophyll; b= 
Bacterio; TPP= Tetraphenylporphyrin; Pheo a= Pheophorbide a; HpD= Hematoporphyrin derivative; PFII= 
Photofrin II'''; MTBP= Metallo-tetrabenzoporphyrins; ZnPc(OH4)= Zn Phthalocyanine tetrahydroxyl; BPD-
MA= Benzoporphyrin derivative monoacid ring A; Pc= Phthalocyanine; NPc= Naphthalocyanine; TNP= 
Tetranaphthaloporphyrin. 
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these physical properties of numerous new second generation photosensitizers in various 
solvents, or organized systems such as liposomes. The <l>à production by photosensitizers 
is usually higher in organic sol vents than in aqueous systems. 
It is apparent from Table 2.2 and McGarvey and Truscott (1990) that most 
tetrapyrroles have a <l>T of around 0.6 to 0.9 and a <l>ll of around 0.5 to 0.8. The 
photosensitization ability of tetrapyrroles can be assessed by these photophysical 
properties of the molecules, however these parameters are usually measured in in vitro 
conditions. It would in general, be beneficial to measure the photosensitization potential 
PDT photosensitizers in a biologically relevant system (McGarvey and Truscott, 1990). 
However, Patterson et al. (1990) indicated that direct 10 2 measurement in vivo is not 
possible at this time, thus the in vitro photophysical mesurements have to be used 
(McGarvey and Truscott, 1990). A simple biological system that can be used to estimate 
oxygen mediated photosensitization in vivo is photohemolysis (Bjellerup, 1988). The 
photosensitization of tetrapyrroles can be estimated using photohemolysis of red blood 
cells into which a photosensitizer has been incorporated (Ben-Hur et al., 1993a). The cell 
membrane lysis caused by activated oxygen species subsequent to irradiation is 
determined by the release of hemoglobin into the medium. Thus photohemolysis is a 
practical method to assess the PDT photosensitizing ability of any new dye, since it can 
be used not only to determine if photosensitization occurs in a biological system, but can 
also be used to study both the light dose and dye concentration on the photosensitization 
process. 
2.1.5 O2 concentration 
Photodynamic action of PDT dyes is oxygen dependent, with the molecular 
acceptor usually being oxygen (Moan and Berg, 1992). This is indicated by the absence 
of photodynamic activity of a PDT photosensitizer without oxygen. Other anti-tumour 
treatments like radiation therapy are only O2 sensitive, in that their activity decreases 
about 2 to 3 times in the absence of oxygen (Moan and Berg, 1992). Thus oxygen must 
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be present in order to have PDT action. 
The oxygen concentration (measured by the partial pressure of oxygen (P02» in 
tumours is generally lower « 40 Torr (5.3 kPa» than in normal tissues (>50 Torr) 
(Freitas, 1985). The low O2 concentration in tumours is due to poor O2 diffusion from 
the circulatory system (Moan and Berg, 1992) and high O2 consumption by the rapidly 
growing neoplastic cells (Jain, 1984). Sorne regions within a tumour may have a P02 
values near zero (Freitas, 1985). The consumption of O2 by the photodynamic process 
can further decrease the oxygen concentration within tumour tissue. For example, O2 
concentration dropped from 21 to less than 3 Torr during PDT treatment (Reed et al., 
1989). With such low O2 concentrations the photodynamic process is certain to be limited 
(Freitas, 1985). 
The O2 concentration within tumour tissue needs to be maintained at near normal 
levels if the photodynamic activity of PDT is not to be limited. The oxygen consumption 
rate of the photodynamic pro cess is usually greater than the diffusion of oxygen into the 
tumour tissue from the blood. There have been sorne successful attempts to increase O2 
concentration before or during PDT treatment so that the photodynamic pro cess would not 
be O2 limited (Freitas, 1985). Oxygen enrichment techniques that have been attempted 
are: i) blood transfusions to maintain high hemoglobin levels; ii) allowing the patient to 
breathe pure oxygen during the treatment; and iii) giving the patient perfluorocarbons 
which are a synthetic material capable of carrying high O2 concentrations. AlI of these 
O2 enrichment techniques have increased the PDT effectiveness which suggests that O2 
was previously limited (Freitas, 1985). 
2.1.6 Tissue damage resulting from PDT 
The two main types of PDT -incurred damage are believed to be i) injury to the 
microvascular system of the tumour and ii) direct intracellular damage (Henderson and 
Dougherty, 1992). The injury to the vascular supply of the tumour results in starvation 
of the tumour (Marcus, 1992). The photodynamic product 102 will react with the cellular 
structures leading to cell damage. The short microsecond lifetime of 102 in biological 
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systems prevents it from diffusing any great distance, which suggests that the location of 
any chemical reaction between 10 2 and biomolecules must occur in proximity to the site 
where the 10 2 was generated. Cell death will occur from the oxidative cellular damage 
caused by 10 2 when that damage exceeds the cellular repair capability of the cell. A 
distinct boundary of necrosis or cell death, rather then a graduaI transition from total 
tissue destruction to little damage, has been observed in numerous PDT treated tumours 
(Bown et al. , 1986). The cellular repair of PDT -incurred damage could explain the 
observed boundary, where necrosis boundary is believed to represent the threshold 
between those regions of the tumour where the cells were able to repair themselves and 
those regions where they were not (Wilson, 1989). 
The intracellular damage to sub-cellular organelles of tumour cells caused by 10 2 
attack can lead to cell death. The degree of sub-cellular photosensitization damage has 
been correlated to the lipophilicity of a photosensitizer such that the more lipophilic dyes 
produce greater PDT induced cellular damage (Henderson and Dougherty, 1992). This 
has been shown by the higher rate of cellular photoina,ctivation with photosensitizing dyes 
that have a higher hydrophobicity measured using Triton X-1141H20 partition coefficients 
(Moan et al. , 1987). More hydrophobic second generation PDT drugs, such as the 
chlorins, are anticipated to have improved PDT response compared to current PDT drugs 
like PFII, due to this correlation between cell inactivation and hydrophobicity . 
2.2 Toxicity 
2.2.1 Cytotoxicity assay 
A rapid method often used to evaluate chemotherapeutic activity of drugs is 
cellular toxicity of tissue cultured neoplastic cells. The MTT assay is a convenient assay 
used to evaluate cellular cytotoxicty (Cole, 1986). MTT, a tetrazolium salt is 
enzymatically converted into a coloured formazan complex by living cells. The presence 
of the coloured product of the MTT by the cell can be used as a measure of cell viability. 
The viability can be estimated by a simple colourimetric assay of the cell suspension. A 
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known cytotoxic agent can be added as a positive control. That positive control would 
kill the cells and thus prevent the coloured product formation . A negative control 
compound can also be used which would not kill the cells and thus the coloured product 
of the MTT can be formed. 
2.2.2 In vivo toxicity 
The acute toxicity of any compound must be evaluated before that compound can 
be used as a drug in clinical trials. The therapeutic index is a ratio of the drug dose 
which causes acute toxicity to that used for treatment. A high therapeutic index implies 
that the dose used for treatment is well below the drug dose that would result in acute 
toxicity, and thus that drug possesses a minimum toxic risk (Gilman et al., 1990). 
The acute toxicity is generally estimated by the LDso (lethal dose for 50% of the 
test cases). The LDso for sorne potential PDT photosensitizers is given in Table 2.3. The 
therapeutic dose for PDT is typically 1-10 mg kg-l , which is approximately 10 times lower 
than the LDso values of those photosensitizers, yielding a good therapeutic index. 
Table 2.3. LDso values for sorne potential PDT photosensitizers. 
Photosensi tizer LDso (mg kg-1) Conditions Reference 
Chlorin e6 189 mlce Kostenich et al., 1994 
Chlorin e6 113 rats Kostenich et al., 1994 
AISPc >100 IV in ratsa Tralau et al., 1990 
HpD 275 IP in micea Tralau et al., 1990 
PlI 130 IP in micea Tralau et al., 1990 
Ca) It should be noted that when investigating acute toxicity using photosensitizers it is necessary to keep 
the animaIs in the dark such that there is no contribution to the results from photosensitization. 
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2.3 Possibility of dual action anti-tumour drugs. 
2.3.1 First observation of anti-tumour activity by a porphyrin derivative 
It was incidentally observed during a recent study on a new series of water soluble 
porphyrin derivatives, that one of these derivatives, namely hematoporphyrin propyl ether 
ethanolamide (HPPEEA), showed anti-tumour activity in the absence of light (Girard, 
1992). Tumour regression was observed in the absence of light when HPPEEA (10 mg 
kg-1 body weight) was administered to SKH-HR1 mice carrying transitional bladder 
carcinoma (FCB). 
It was concluded that the ethanolamide moiety of HPPEEA must be involved in 
the anti-tumour activity since no porphyrin derivative until that time had ever shown 
chemotherapeutic activity in the absence of light. It was realized upon closer examination 
of the chemical structure of the ethanolamide moiety that there was sorne correlation to 
the structure of the nitrogen mustards, which are a class of alkylating chemotherapeutic 
drugs. 
2.3.2 Nitrogen mustards 
The nitrogen mustards are a diverse class of compounds which share a common 
structural moiety. This structural moiety consists of a nitrogen attached to one or more 
ethyl halide(s) (Fig. 2.3). The ethyl halide can undergo a rearrangement to form a 
metastable intermediate called an aziridinium ion, with the concomitant removal of the 
halide (Calabresi and Chabner, 1990). The metastable aziridinium ion intermediate is a 
three membered ring consisting of the nitrogen and the two carbons of the ethyl group 
(Fig. 2.3). The aziridinium ion intermediate can form spontaneously when a nitrogen 
mustard is introduced into an aqueous environment. This aziridinium ion intermediate is 
a very reactive electrophile, which can undergo alkylating reactions with other 
nucleophilic molecules. 
The principal anti-tumour reactivity of nitrogen mustards involves their interaction 
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with a DNA molecule (Calabresi and Chabner, 1990; Calsou and Salles, 1993). An SN2 
type nucleophilic attack by the N-7 of the guanine base of DNA on the aziridinium ion 
intermediate leads to the alkylation of DNA (Kohn, 1981 ; Calabresi and Chabner, 1990) 
(Fig. 2.4). The result of the nitrogen mustard binding to the guanine is a defect in the 
DNA strand. A cross-link between two guanine bases on adjacent DNA strands can also 
occur if the nitrogen mustard contains two alkylating moieties. Rapidly proliferating cells, 
such as those in neoplastic tissues, are the most sensitive to these DNA cross-links, thus 
a selective tumour toxicity can be achieved. 
~Cl CH 
r-{ €el ,,2 RN-CH R-N:J ~2 + CI ~ 
CI CI 
Nitrogen mustard meta-stable 
aziridinium ion 
Figure 2.3. The nitrogen mustard rearrangement into the meta-stable aziridinium ion 
intermediate. 
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1 
Hc* 1 7H 
° 
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Figure 2.4. DNA-nitrogen mustard reaction scheme. The nitrogen mustard reacts with 
the N-7 nitrogen of guanine bases of DNA. A second similar reaction with the adjacent 
DNA strand leads to a cross-link. 
The SN2 nucleophilic attack on the aziridinium ion intermediate is not exclusive 
to reaction with DNA. The aziridinium ion moiety can also react with other substrate 
molecules, such as H20 . The reaction of H20 with aziridinium ion, which is significant 
in biological tissues, leads to the formation of an ethanolamide (Wilman and Connors, 
1983). The reaction of an aziridinium ion with H20 to form an ethanolamide occurs 
when the Cl of the ethyl halide is exchanged by an OH from the H20 (Fig. 2.Sa). The 
ethanolamide is likely to have lower alkylating reactivity than the nitrogen mustards, due 
to slower formation of the aziridinium ion intermediate, as -OH is a poorer leaving group 
than Cl-. However, the conversion of an ethanolamide into an aziridinium ion 
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intermediate might become more favourable, under certain biological conditions. One 
such situation can be found in the blood, where the high Cl- concentration favours the 
exchange between OH and Cl thereby converting the ethanolamide into a nitrogen 
mustard via an aziridinium ion (Wilman and Connors, 1983). Another plausible condition 
occurs in acidic medium, in which the higher hydronium ion concentration could induce 
the formation of an aziridinium ion via the formation of an oxonium ion, the latter being 
a good leaving group (Fig. 2. Sb). Tumour tissue is often more acidic than normal tissue 
(Tannock and Rotin, 1989), thus the latter situation becomes a possible explanation for 
the observed anti-tumour activity of the porphyrin ethanolamides. 
The nitrogen mustards show selective alkylating reactivity toward neoplastic 
tissues, while tetrapyrroles are selectively retained by such tissues. Thus a cyclic 
tetrapyrrole ethanolamide could be expected to have both selective retenti on and anti-
tumour activity, providing that the tissue environment is favourable to the formation of 
the aziridinium ion intermediate from the ethanolamide moiety. A tetrapyrrole 
ethanolamide derivative could be seen as a potential dual action chemotherapeutic 
photosensitizer, due in part to the photosensitization property of the tetrapyrrole unit and 
in part to the anti-tumour alkylating property of the ethanolamide moiety. 
A 
CCI 
R-N(3 ---. 
~ a 
B 
Cl 
nitrogen 
mustard 
OH 
~ +HEI) 
R-N: ,... 
'------ 'El) ~ -H 
OH 
ethanolamine 
r'i9.:H R-~~ H---. 
œ~b 
Ci 
~OH 
R -N: ---.---. 
~a b 
CI 
34 
~OH 
R-N: 
~ 
OH 
aziridinium 
ion 
hemiethanolamine ethanolamine 
oxonium ion 
o~ 
"C-NH 
aziridinium 
ion 
Nu 
~ 
R-N: 
~OH 
alkylated 
ethanolamine 
Tetrapyrrole ~ , R -CH2 CH2CH20H 
Ethanolamide 
group 
Figure 2.5. (A) The reaction scheme by which a nitrogen mustard changes to an 
ethanolamine due to an attack of the aziridinum ion by H20 . (B) The reaction scheme 
by which an ethanolamine in an acidic environment can form an aziridimium ion which 
can undergo a nucleophilic attack to form an alkylated ethanolamide. The tetrapyrole 
ethanolamides are very similar to the ethanolamines formed by interaction between a 
nitrogen mustard and H20 . 
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2.4 Chlorins 
2.4.1 Sources of chlorins 
Large quantities (gram size) are required if a potential new photosensitizer dye is 
to be used in clinical trials. The requirement for such large quantities has led to synthetic 
difficulties with many new dyes, including the chlorins. It is difficult by de novo 
synthesis to produce adequate quantities of purified chlorins due to the isomeric mixtures 
which frequently are produced during the synthesis and which are difficult to separate 
(Montforts et al., 1994). Previous studies using mixed compounds or formulations (for 
example HpD) have Ied to un certain results (Bonnet and Berenbaum, 1989). Altemately, 
chlorophyll and other natural cyclic tetrapyrroles can be used as starting materials for the 
synthesis of chlorins, so that many of the difficulties associated with de novo synthesis 
can be avoided (Montforts et al. , 1994). There are two necessary steps if a compound 
from a natural source is to be used in organic synthesis: i) isolation and purification of 
the compound from the natural source; and ii) modification of that molecule into the 
desired product. Chlorophyll a (ChI a) was used as the starting material in the synthesis 
discussed here. 
2.4.1.1 Chlorophyll a isolation 
Isolation and purification of ChI a (Fig. 1.2) from plant sources has been 
documented by Strain and Svec (1966), Svec (1991), and Pandey et al. (1991). A 
common ChI a source is the spinach plant because of its abundance and accessibility . 
The purification of ChI a from spinach is somewhat troublesome due to the presence of 
both ChI a and b (Strain and Svec, 1966; Svec, 1991 ; Rahmani et al., 1993). The blue-
green alga Spirulina which contains no ChI b has also been used as a source for ChI a, 
in order to simplify the extraction and purification, but the alga requires elaborate growth 
apparatus (Pan dey et al. , 1991). 
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The first step in isolating Chi a from plants is to make a crude extract of the plant 
pigments. Purification of the Chi a from the crude pigment extract is usually done by 
liquid column chromatography (Strain and Svec, 1966; Svec, 1978; Brockmann and Risch, 
1991 ; Pandey et al. , 1991). The col umn's stationary phase is usually one of the 
following : powdered sucrose, cellulose, silica gel , or alumina (Strain and Svec, 1966; 
Brockmann and Risch, 1990). The ChI a bands from the column can be tested for purity 
by spectroscopy and high pressure liquid chromatography (HPLC) (Roy, 1987; Shioi, 
1991). The ChI a of sufficient purity is then ready for use in the synthesis of chlorin type 
PDT drugs. 
2.4.1.2 Synthesis using chlorophyll a 
Chlorins synthesized from Chi a for use as PDT photosensitizers have previously 
been reported. Chlorophyll a was modified by the addition of amines in the late 1960's 
(Pennington et al. , 1967) and the use of these chlorin amide derivatives for PDT was 
suggested by Gurinovich et al. (1992). Chlorin e6 ethylenediamide was synthesized by 
Gurinovich et al. (1992) using a synthesis scheme detailed by Pennington et al. (1967) . 
The synthesis of other chlorin derivatives of Chi a are described in detail by Pandey et 
al. (1991), and Montforts et al. (1994) . Refer to Figure 3.2 for a detailed reaction scheme 
used in this research project. 
2.4.2 Chlorin spectroscopy 
Spectroscopy is a useful tool which can be used to identify and examine organic 
synthesis products, such as the chlorins. The visiblelight absorption of a potential PDT 
photosensitizer must be known, since visible light is used in PDT for excitation. The UV-
visible absorbance spectrum of chlorins can be compared to that of the parent compound 
ChI a, which is weIl documented (Brown, 1968; Scheer and Katz, 1978; Hynninen et al. , 
1979; Hoff and Amesz, 1991 ; Rahmani et al. , 1993 ; Brereton et al. , 1994) (Fig. 2.6 (a)). 
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The two major absorption bands for Chi a in diethyl ether are at 428.5 and 662 nm and 
have molar extinction coefficients of 1.358 x 105 and 1.007 x 105 M-l cm-l, respectively 
(Brown, 1968). 
Reactions of the carbonyi groups of chlorins during synthesis can be monitored 
by IR spectroscopy (Pennington et al., 1967, 1964; Scheer and Katz, 1978). The carbonyl 
region of the IR spectrum (between 1750-1600 cm-l) (Fig. 2.6 (b» is particularly usefui 
in monitoring changes to carbonyl groups on chlorins (Katz et al. , 1966; Chapados, 1988; 
Lutz and Mantele, 1990; and Okada et al. , 1993). For example in Chi a the C=O esters 
at positions C-7 and C-I0 (Fig. 1.3 for carbon numbering) are responsible for the band 
at 1730 cm-l and the C=O ketone carbonyi at position C-9 is responsible for the band at 
1700 cm-I(Katz et al. , 1966; Chapados, 1988). The carbonyl bands in the IR spectrum 
can move by as much as 50 cm-l depending on the solvent environment surrounding the 
moiecule (Lutz and Mantele, 1991). 
By using l3C NMR the ketone carbonyl carbon (C-9) of ring V of chlorophyll type 
molecules can be monitored, producing a tine at 189-195 ppm in the l3C spectrum (Fig. 
2.6 (c» when ring V of Chi a is intact (Katz and Janson, 1973 ; Smith and Unsworth, 
1975; Katz et al., 1978; and Abraham and Rowan, 1990). When ring V of ChI a is 
opened during a synthesis the C-9 carbonyl carbon is reassigned to C-6a (observed at 172 
ppm) and the 189 ppm tine disappears (Smith and Unsworth, 1975). The new tine at 
172.4 ppm produced by C-6a is difficult to distinguish from that of C-7 (172.8 ppm), 
because both carbons are similar alkyl-type carbons. 
This brief discussion of synthesis and spectroscopy of chlorins and Chi a is 
intended to provide sorne basic understanding of the field. The background provided here 
will be reexamined during the discussion of the synthesis carried out in this study. 
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Figure 2.6. Chlorophyll a spectra: (a) electronic absorption in diethyl ether, (b) 
IR in CCLi pyridine, and (c) l3C NMR in deuterated THF. (adapted from (a) Hoff and 
Amesz, 1990, (b) Katz et al. , 1978, and (c) Katz and Janson, 1973). 
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2.5 Aim of present work 
The original porphyrin ethanolamide derivatives synthesized by Girard (1992) were 
primarily developed for spectroscopic studies. They exhibited rather poor selectivity for 
neoplastic tissues and somewhat limiting absorbance in the far red, yet these porphyrin 
ethanolamides did show both chemotherapeutic and photohemolytic activity . The aim of 
the work described here was to synthesize another ethanolamide derivative, using a 
chlorin which is known to have higher absorbance in the far red, and to examine its 
chemotherapeutic and photochemotherapeutic activity, in order to hopefully develop more 
potent dual action anti-tumour drug. 
The scope of this project included: i) synthesis of pheophorbide a ethanolamide 
(PEA) starting from ChI a; ii) purification of PEA; and iii) evaluation of its toxicity, 
chemotherapeutic, pharmacokinetics, and photosensitization effects both, in vitro and in 
vivo where possible. The chemotherapeutic activity of PEA was evaluated by its 
cytotoxicity toward human cancer cell lines and its effect on animal cancer models. In 
order for PEA to be a potential photochemotherapeutic agent it must demonstrate both 
selective localization in tumours and photosensitization. The two properties used to assess 
the photochemotherapeutic activity of PEA were its pharmacokinetic behaviour in animal 
tumour models, and its photohemolytic activity . The pharmacokinetic data were used to 
demonstrate selective localization of PEA in tumours. The photohemolysis results were 
used to demonstrate the photosensitization activity of PEA. The goal of this work was 
thus to establish whether PEA was a potentially useful dual-action anti-tumour drug. 
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Chapter 3 Experimental 
3.1 Chlorophyll extraction from spinach 
ChI a was extracted from locally purchased spinach leaves by solvent extraction 
(Fig. 3.1). The plants leaves were deribbed and separated into 100 g (fresh weight) lots. 
Methanol (500 mL), 0.5 g NaH2C03 and 100 g spinach were combined in a 1 liter flask. 
The leaf tissue was homogenated into a pulp using a tissue homogenator (Mo dei L-04719-
00 Cole Parmer). Room temperature was maintained during the grinding. The methanol 
was separated from the pulp by gravity filtration through fluted Whatman #1 filter paper. 
AlI methanollots were pooled, and the extracted dye was partitioned into petroleum ether 
(35-60 oC grade), by adding equal parts petroleum ether (pet ether) and water. The water-
methanol partition was discarded, and the pet ether fraction was further washed with a 50 
mM NaCI-H20 solution (Folch et al., 1957). The resulting crude pigment extract was 
dried by rotary evaporation. 
The pigments in the crude extract were separated by liquid column 
chromatography. The silica (Davisil silica 300 A 90-130 f.lm AlItech Mandel Scientific) 
columns were 5 cm by 200 cm with a mobile phase of 5% n propanol in pet ether. The 
pigment was dissolved in a minimum volume of solvent (typically < 5 mL) and placed 
on the top of the column. Elution began after 10 min during which the pigments were 
allowed to adhere to the silica. Mobile phase solvent was continuously added until the 
blue-green ChI a band was eluted from the bottom of the column (Fig. 3.1). The silica, 
with the remaining pigments, was then removed for bulk cleaning and reused. The ChI a 
fraction was dried by rotary evaporation. 
The silica was regenerated in bulk by washing with acetone and then with distilled 
water. The silica was mixed with acetone into a thick slurry and heated to 80 oC while 
stirring, then allowed to cool. The acetone was removed by vacuum filtration . The 
procedure was repeated using distilled water. The silica was dried at 100 oC for 5 days 
before reuse. 
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Figure 3.1. Flow diagram of chlorophyll extraction and purification procedure. 
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3.2 Conversion of chlorophyll a to methyl pheophorbide a 
ChI a was immediately converted into methyl pheophorbide a (mPheo) by 
removing the phytyl chain and coordinated Mg+2 (see Fig. 3.2) . Acidic methanol (Moser 
et al. , 1992) was prepared immediately before use by adding anhydrous H2S04 to 
anhydrous methanol (10 mL to 90 mL) and cooling to room temperature. Chlorophyll a 
was added to the reaction mixture (1 g per 100 mL acidic methanol) and stirred, while 
maintaining a gaseous nitrogen environment. The progress of the reaction was monitored 
by testing aliquots at intervals on silica thin layer chromatography plates (TLC) using 5% 
methanol in dichloromethane as a mobile phase. 
When the reaction reached completion (about 2 h as confirmed by TLC), mPheo 
was partitioned into chloroform by adding equal parts chloroform and water. The 
chloroform fraction was washed several times with distilled water, and then washed with 
a 10% sodium bicarbonate solution to remove any remaining acid. The mPheo was 
obtained by drying with anhydrous sodium sulphate followed by evaporation of the 
solvent in a rotary evaporator. 
Methyl pheophorbide a was purified to rem ove the alkyl debris, resulting from the 
excised phytyl chain, by silica column chromatography, using a 2.5 cm by 200 cm column 
with a mobile phase of 5% methanol in dichloromethane. The mPheo was dissolved in 
a minimum amount of the mobile phase (typically < 3 mL) and placed at the top of the 
column. After 10 min, to allow the mPheo to adhere to the silica, the mobile phase was 
added continuously until the dark green mPheo band was eluted from the bottom of the 
column. The silica containing the remaining pigments was then removed for bulk 
cleaning. The mPheo purity was tested by silica TLC, as per the method for ChI a . This 
method did not detect the presence of any alkyl fragments . In order to view the alkyl 
fragment band, the TLC was sprayed with concentrated H2S04 and heated to 100 oc. 
This procedure chars hydrocarbons, thus allowing such bands to become visible. The 
mPheo fraction was dried as above and stored at -3 oC in vials purged with N2. 
CH30H 
OCH3 
Mg 
Phytyl 
Chlorophyll a 
Methyl pheophorblde a 
H 3CO 
Pheophorbide 
Ethanolamide 
H 3CO 
Ethanolamine 
Figure 3.2 Synthesis of PEA from chlorphyll a . Chlorophyll a is converted to methyl pheophorbide a 
by the loss of Mg and the phytyl chain. Methyl pheophorbidea and ethanolamime react to produce PEA. 
""" w 
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3.3 Ethanolamide synthesis 
3.3.1 Pheophorbide a ethanolamide 
PEA was synthesized from mPheo and ethanolamine (see Fig. 3.2). Methyl 
pheophorbide a (1 g) was added to dioxane (20 mL) and ethanolamine (10 mL). The 
reaction mixture was stirred under nitrogen. The progress of the reaction was monitored 
by regular samples tested on silica TLC plates using 5% methanol in dichloromethane as 
the mobile phase. The conversion reaction of mPheo to PEA usually took about 2 h. 
When the reaction was completed (as determined by TLC), PEA was partitioned 
into chloroform by adding equal parts chloroform and water. The chloroform layer was 
washed several times with water, then neutralized by adding dropwise concentrated HCI 
and testing with pH paper until pH=7. The chloroform layer was dried with anhydrous 
sodium sulphate and evaporated. PEA was purified by silica column chromatography 
using the same procedure as outlined for mPheo. PEA eluted from the column was dried 
as above and then placed in a Fischer pistol for 7 h at 80 oC. PEA was stored in vials 
purged with nitrogen at -3 oC. The chemical structure of PEA was confirmed by IR and 
NMR spectroscopy data. 
3.3.2 HPPEEA synthesis 
It was necessary to synthesize large quantities of HPPEEA for comparison studies 
between HPPEEA and PEA. The synthesis was preformed exactly as outlined by Girard 
(1992) producing similar yields. 
3.4 HPLC analysis of Pheophorbide a ethanolamide 
The purity of PEA was tested by HPLC. HPLC techniques for analysis of chlorins 
have been reviewed by Roy (1987). The procedure of Mantoura and Llewellyn (1983) 
was used for the HPLC of PEA. An important point in this HPLC procedure was the use 
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of an ion pair reagent. The ion paired reagent improves the separation of compound that 
are very polar or can have multiple ionized forms (Roy, 1987). It was necessary to 
precondition the PEA sample prior to use in the HPLC in order to assure that the ion 
paired reagent functioned properly. This preconditioning involved dissolution ofPEA (0.5 
mg) in 1 mL of 90% acetone. Then 300 ilL of the ion pair reagent was added and at least 
5 min was allowed for ion pair association with the sample prior to analysis. If the ion 
pair association had not occurred then the separation on the column was found to be poor. 
The HPLC column used was a 3x3 Econosphere, fully end capped, C18 (Mandel 
Scientific) in a gradient solvent system HPLC (ISCO model 2360). The gradient consisted 
of 100% solvent A to 100% solvent B in 10 min. Solvent A contained ion pair 
reagent!H20/methanol in a ratio of 10/10/80 (v/v/v) and solvent B contained acetone/ 
methanol in a ratio of 20/80 (v/v). The ion pair reagent contained 1.5 g tetrabutyl-
ammonium acetate and 7.7 g ammonium acetate in 100 mL of distilled H 20 . Detection 
of the products was acheived by light absorption at 405 nm. 
3.5 Spectroscopy of chlorins 
Absorbance, fluorescence excitation, and fluorescence emlSSlOn spectra were 
recorded for both mPheo and PEA. The compounds were dissolved in dichloromethane 
for absorption and fluorescence measurement sin ce they were only slightly water soluble. 
AH absorption measurements were recorded on a Shimadzu UV -160 spectrometer with 
a 3 nm spectral resolution, using 1 cm pathlength quartz cuvettes. AlI fluorescence and 
fluorescence excitation spectra were recorded on an LS-I00 spectrofluorometer (PTI) . 
This instrument has variable sht widths in b6th the excitation and emission 
monochromaters. Typical slit widths were 1 mm in both monochromaters, providing 
spectral resolutions of 0.5 nm. Emission spectra were obtained by excitation at the peak 
of the Soret band (413 nm and 401 nm for mPheo and PEA respectively). Excitation 
spectra were obtained by monitoring the intensity at the peak of fluorescence emission 
(680 nm for both mPheo and PEA) while scanning the excitation wavelengths. In order 
to prevent the phenomenon of self absorption in the sample cuvette, the absorbance of aIl 
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solutions studied was less than 0.1. 
Infrared measurements were made on a Nicolet (model 51 OP) FTIR using a diffuse 
reflectance accessory (Harrick, model HVC-DR2). The spectral resolution of the 
instrument was set at 2 cm-I and the spectral range was from 4000 to 600 cm-I . The 
samples were prepared as a loose powder in ground KBr. 
l3C NMR was preformed on a Varian (model Gemini 200) NMR. The samples 
were analyzed as solutions in deuterated chloroform. 
3.6 Animal and tumour models 
For the different types of experiments performed when evaluating the tetrapyrroles, 
several different breeds of mice were used (Table 3.1). The C57-BL6 mice are a black 
skinned and haired mouse commonly used in chemotherapy testing. The SKH-HRI is a 
mouse breed that is genetically similar to the C57-BL6, therefore it can also carry the 
C57-BL6 tumour lines. The Balb C mice are pink skinned, white haired mice that are 
commonly used as mouse models for various cancer studies. The B6D2F 1 mi ce are black 
skinned and haired mice which are a cross between DBA and C57-BL6 mice, which can 
carry tumours from both breeds. These animaIs can carry a wide variety of available 
tumour lines. 
Table 3.1. The different breeds of mice used and sorne of their physical characteristics. 
Breed Skin type Hair type 
SKH-HRI Pink (similar to hum an) Hairless 
C57-BL6 Black pigmented Black 
B6D2FI Black pigmented Black 
Balb C Pink (similar to hum an) White 
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Tumours were purchased from the NCI-Frederic Cancer Research and 
Development Center (Building 432, Frederick, MD 21701). The tumour lines used in the 
investigations are summarized in Table 3.2. Tumours were maintained by live transfer 
into suitable hosts. For tumour suspension type implants of solid tumours, tumours were 
removed when they were approximately 10 mm in diameter and placed in physiological 
saline (150 nm NaCl) . The tumour tissue was cut into 1 to 2 mm cubes. The tissue was 
further homogenized by repeatly passing through a syringe, which was performed by 
placing a 1 mL syringe at a slight angle against the bottom of a beaker and drawing the 
tumour tissue rapidly up and down in the syringe. The shear force, as the tissue passed 
through the syringe causes the tissue to break into smaller pieces. Thus, the generated 
tissue suspension was inj ected subcutaneously into the mouse using a 16 gauge needle. 
AnimaIs were anesthetized with ketamine (Rogarsetic® (rogar/STB Inc, London Ont.), 
dose = 100 to 120 mg kg-1 body weight) by intraperitoneal injection. Tumours reached 
10 mm diameters in about 10 days. The P388 leukemia was transferred differently 
because it was an ascites cancer. This cancer migrates throughout the whole body forming 
a cell-filled ascites fluid. This fluid is removed by a syringe and diluted to a suitable cell 
number, usually about 1000 cells. Then the cell suspension is inj ected intraperitoneal into 
another suitable host. 
Table 3.2. Mouse tumour lines and their general characteristics. 
Tumour line 
Lewis lung 
P388 
EMT-6 
M4898 
Host 
C57-BL6 
B6D2F 1 
SKH-HRI 
B6D2F1 
Balb C 
Balb C 
Characteristics 
Solid tumour, lung carcinoma, 
metastatic 
Leukemia, ascites cancer 
Mammary adenocarcinoma, 
solid tumour 
Lung adenocarcinoma, 
solid tumour 
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3.7 Injectable solvent 
Any new drug has to be tested for solubility in an injectable solvent formula. A 
suitable injection formulation for both HPPEEA and PEA was found to consist of a 
mixture of DMSO and serum. The drug studied was dissolved in DMSO and then diluted 
with human serum. The maximum concentration of DMSO used in the injection 
formulation was 10%, with human serum accounting for the balance of the solution. The 
maximum drug concentration obtained using this solvent formulation was typically 4 mg 
mL- I . Other emulsifier formulations such as CRM were not able to provide sufficient 
drug concentrations with these ethanolamides. 
3.8 Acute toxicity evaluation 
The drug to be tested for toxlClty was dissolved in the injectable solvent to 
produce a stock solution. The stock solution was either 1 or 4 to 5 mg mL- I . The drug 
was injected intraperitoneally and the animaIs were observed for acute or chronic toxicity . 
Due to the limited drug solubility, it was necessary in sorne tests using the higher drug 
doses to administer the drug over several days, in several injections. No single injection 
into an animal exceeded 1 mL. The drugs tested for acute toxicity were HPPEEA, PEA, 
and polyhematoporphyrin. Polyhematoporphyrin, (University of Leeds, Leeds, UK) is 
believed to be equivalent to PFn (Vernon et al., 1995). Due to the limited solubility the 
highest HPPEEA dose was injected as 7 daily injections of 100 mg kg-l and the highest 
PEA dose was injected as 3 daily injections of 166 mg kg-l . 
3.9 Chemotherapy 
3.9.1 MTT cytotoxicity assay 
The MTT cytotoxicity assay involves the measurement of cell viability after 
treatment with cytotoxic agents by the colorimetric change of the MTT dye (Cole, 1986). 
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The cells are placed in 96-well flat bottomed tissue culture trays. The drug is added after 
24 h at the stated concentrations (0.001 to 100 /lM). The cells are grown in the presence 
of the cytotoxic drug for 4 days, then the MTT dye is added. The dye is enzymatically 
converted to a coloured formazan in metabolically active living cells (Slater et al. , 1963 ; 
Cole, 1986). Those cells that have been damaged or killed by the cytotoxic agent will 
not pro duce the blue coloured formazan dye, which is measured by light absorption at 570 
nm using a Dynatech model MR600 plate reader. Each drug concentration was tested in 
quadruplicate in each experiment. The drugs tested were: adriamycin (Sigma Chemical 
Corn, St. Louis, Mo, USA), a chemotherapeutic agent; polyhematoporphyrin (pHP); 
hematoporphyrin IX (HPIX) (Porphyrin products, Logan, Utah, USA); HPPEEA; mPheo; 
and PEA. The cell lines used for the assay are summarized in Table 3.3. 
Table 3.3. Tissue culture cell lines used in MTT assay. 
Line 
K562 
Raji 
Daudi a 
HeLa 
H69 
2780.9s 
MDA.MB 
S1HA 
Origin 
Human erythroleukemia 
Human burkitt lymphoma 
Human burkitt lymphoma 
Human cervical carcinoma 
Human small celllung carcinoma 
Human ovarian carcinoma 
Human breast adenocarcinoma 
Human cervical squamous carcinoma 
(a) Used only for IC50 study (Table 4.7, Fig. 4. 19 and 4.20) 
3.9.2 Solid tumour in animais 
Lewis lung carcinoma was implanted into C57-BL6 mice. The treatment began 
when the tumours reached 5-6 mm in diameter. The HPPEEA or PEA were administered 
by IP inj ections daily to the animaIs at a dose of 10 mg kg-l body weight. The control 
50 
animais were administered the injection solvent only in a similar manner. The treatment 
was evaluated by measurement of the progression of tumour diameter. Animais were kept 
in the dark for the duration of the experiment in order to prevent any phototherapy. 
3.9.3 Leukemia cancer in animais 
P388 leukaemia cancer was established in B6D2F1 mice. The following day after 
the cancer was injected, the chemotherapeutic treatment began. The drugs, HPPEEA and 
PEA, were injected intraperitoneally at the stated dose. The progression of the cancer was 
followed by monitoring the weight of the animal. The results are reported as the percent 
weight increase of the animais from the beginning of the treatment. Animais were kept 
in the dark for the duration of the experiment so that no phototherapy could occur. 
3.10 Pharmacokinetics 
3.10.1 In vivo pharmacokinetics 
In vivo pharmacokinetics is a rapid qualitative method to follow drug clearance 
from various anatomicallocations, which involves monitoring the drug non-invasively by 
measuring the drug fluorescence from the tissues. Three animais were injected 
intravenously via the femoral vein with each of the fluorescent drug tested (HPPEEA, 
mPheo, or PEA) at a dose of 10 mg kg-1 body weight. At 15 min intervals the animal was 
positioned at the analysis site of a bifurcated fiber bundle (Fig. 3.3). One branch of the 
fiber bundle provided the excitation irradiation and the other carried the fluorescence 
emission from the drug to the spectrograph and photodiode array (Princeton Instrument 
model SMCP 700G). The analysis end of the fiber bundle was in a coaxial configuration 
with the center leading to the excitation bran ch of the fiber and the outside ring leading 
to the photodiode array emission spectrophotometer (Fig. 3.4); the branch fiber ends were 
formed into a rectangle slit configuration with a two to one aspect ratio. The excitation 
source was a 75 W xenon arc lamp coupled to a 0.22 meter monochromater (PT!) set at 
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400 nm. The pharmacokinetic data were monitored via the fluorescence intensity of the 
drug at the peak of its emission spectrum (615 nm for HPPEEA; 680 nm for rnPheo and 
PEA). The fluorescence intensity was corrected for instrumental variation within an 
experiment with a standard solution of uroporphyrin (Porphyrin Products, Logan, Utah, 
USA). 
Several anatomical sites were monitored, namely the abdomen, thigh, tumour, and 
skinfold. Each site represents a composite fluorescence intensity arising from a group of 
organs. The abdomen site represents a combined signal from the skin, liver and internaI 
organs; the skinfold represents the skin and sorne fat tissue; the thigh represents muscle 
and skin; and the tumour site represents skin and tumour tissue. 
3.10.2 Ex vivo pharmacokinetics 
AnimaIs were injected intravenously into the femoral vein with the drug (HPPEEA 
or PEA) at a dose of 10 mg kg-! body weight and sacrificed at timed intervals up to 48 
h post injection. 
3.10.2.1 Serum measurements 
For the serum measurements the animaIs were asphyxiated to near death with 
propane. Immediately, the whole blood was removed by cardiac puncture and the serum 
was separated by centrifugation in a desk top centrifuge. The fluorescent drug (HPPEEA 
and PEA) was extracted into chloroform/methanol (2: 1 v/v) from the serum (100 ilL 
serum added to 4.9 mL of chloroform/methanol). The fluorescence of the drug in the 
chloroform/methanol was measured in a spectrofluorometer in a manner similar to that 
for fluorescence solution studies ofHPPEEA and PEA (section 3.5). Drug concentrations 
were determined with the use of a standard curve of known drug concentration in the 
same solvent composition. 
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BIFURCATED FIBER BUNDlE 
RECTANGULAR BRANCH ENDS COAXIAL COMMON END 
Figure 3.4. Fiber bundle conformation used for pharmacokinetic measurements. 
The fluorescence intensity was also measured from a known concentration of PBA 
in the presence or absence of serum in order to determine whether or not the serum was 
affecting the fluorescence signal from the drug. The determination was achieved by 
comparing the fluorescence intensity from PBA, obtained from the following solvents: 
i) 5 mL of chloroform/methanol (2:1 v/v); and ii) 4.9 mL of chloroform/methanol plus 
100 ilL of mouse serum. 
3.10.2.2 Tissue measurements 
For the tissue measurements the animaIs were asphyxiated to death with propane. 
Bach tissue of interest was removed, washed in physiological saline (150 mM NaCI) to 
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remove debris and body fluids, and placed in a tissue cuvette for fluorescence 
measurements. The tissue cuvette consisted of a 1 mm spacer between two 1 mm thick 
glass plates so that the tissue thickness was consistently 1 mm thick (Fig. 3.5). The tissue 
pharmacokinetics and clearance curves were then obtained from the tissue fluorescence, 
in the same manner as the in vivo measurements. The fluorescence measurements were 
corrected for instrumental variation in the same manner as the in vivo mesurements. 
3.11 Photohemolysis 
Photohemolysis involves the measurement of hemoglobin released from damaged 
red blood cells by absorption spectroscopy. The red blood cell damage is a result of 
photosensitization by the drug. The red blood cells and photosensitization drug are 
combined in the presence of light for a specified light dose. After 24 h in the dark the 
amount of hemoglobin released from the damaged cells was measured. A flow diagram 
of the procedure is presented Fig. 3.6. 
Human whole blood (0.75 mL) was washed three times in TBS (5 mM tris and 
150 mM NaCl, pH=7.4 unless otherwise stated) and added to 500 mL of TBS. This stock 
blood solution had an absorbance of about l.5 at 414 nm when all hemoglobin was 
released from the cells. The blood stock solution was dispensed in 10 mL aliquots into 
100 mm standard plastic petri dishes (Fig. 3.6). The drugs were dispensed in ilL 
quantities into the petri dishes containing the blood in the dark in order to give the 
required nM drug concentrations. The solvent (95% ethanol) used did not cause any 
hemolysis. After addition of the drugs, the petri dishes were gently agitated. The drugs 
tested were: pHP; HPIX; HPPEEA; mPheo; and PEA. 
The light source used for the light treatment is composed of a light table with a 
plexiglass top and with two 96" VHO cool white fluorescent lamps, giving 9 mW cm·2 
of white light to the samples (Fig. 3.6). The petri dishes were exposed to : 1) no light; 
2) 5 min; or 3) 10 min of light and then removed and placed in the dark for 24 h. The 
samples were then collected and centrifuged at 2000 rpm at 5 oC after the 24 h dark 
period. The released hemoglobin from lysed cells found in the supernatant was measured 
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by absorption at 414 nm (the peak of the hemoglobin Soret band). The percent hemolysis 
was calculated by comparison with a standard curve. The 100% hemolysis reference was 
generated by lysis of a 10 mL aliquot of the same washed red blood cells as used for the 
sampi es with distilled water. The hemoglobin absorption at 414 nm was not affected by 
the drug due to the low drug concentrations in the samples. 
l mm 
TISSUE CUVETTE 
Figure 3.5. Tissue cuvette design. A 1 mm brass spacer separated the two glass plates. 
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Chapter 4 Results 
4.1 Isolation of chlorophyll a 
The starting material selected for PEA synthesis was ChI a, isolated from spinach, 
because of the availability and reasonable cost. The pigments extracted from the spinach 
pulp, after partitioning into petroleum ether, were washed several times with 50 mM 
NaCI-H20 (Folch et al. , 1957) to remove polar lipids. Poor separation of the ether and 
water phases resulted in a lower pigment yield if these salt washes were not performed, 
due to the pigment-ether being discarded with the H20 washes. 
Immediately after pigment extraction the ChI a was separated on the silica 
colurnns. The pigment sample was allowed to adhere to the silica on the column for at 
least ten minutes before the column elution began. The separation was poor if the 
pigment was not allowed to adhere to the silica for that time. The second visible band 
in the column was the blue-green ChI a. A typical elution time was about 1 h, but varied 
somewhat due to the packing of the silica in the colurim and the elution solvent flow rate. 
The purity of the ChI a eluted from the column was confirmed by thin layer 
chromatography (TLC). 
4.2 Synthesis and purification of methyl pheophorbide a 
The synthesis of mPheo proceeded immediately after ChI a was eluted from the 
column so that degradation of ChI a would be minimized. The alkyl fragments, a 
byproduct from the phytol chain cleavage, were detected by TLC in the mPheo product 
and removed by further silica column separation. 
The typical yield of purified mPheo from spinach was 0.07 % by weight (0.752 g 
of mPheo was obtained from 1200 g fresh weight of spinach). If one assumes 98% water 
content in the fresh weight then a 1200 g sample is equal to 24 g dry weight; which 
results in a yield of 3.13 % for mPheo based on dry weight. A 1200 g fresh weight 
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spinach batch was the largest that could be utilized with the experimental equipment 
available in a single extraction procedure. Thus 0.75 g of mPheo could be produced in 
about two days laboratory work. 
4.3 Synthesis and purification of PEA 
PEA (Fig. 4.1) was synthesized from mPheo by replacing the methyl esters on 
mPheo with ethanolamine. The conversion from mPheo to PEA took approximately 2 h. 
The product (PEA) was partitioned into chloroform after completion of the reaction. The 
PEA containing chloroform layer required neutralization with HCI to a neutral pH for 
complete separation of the chloroform and aqueous phases. 
PEA was purified by column chromatography similarly to mPheo. PEA was 
stored in sealed vials at -3 oC that had been purged with nitrogen gas. A typical yield of 
PEA from mPheo was about 45% by weight (2.l1 g mPheo yielded 0.96 g PEA). 
4.4 Verification of the purity of PEA by HPLC 
It was necessary to confirm the purity of PEA after completion of its synthesis. 
HPLC analysis was performed although TLC had indicated a single homogeneous 
compound. Methyl pheophorbide a had a retention time of 7.2 min (Fig. 4.2). PEA, a 
more polar compound, had a retention time of l.5 min (Fig. 4.3). PEA was estimated to 
have a purity of 95% based on the HPLC (Fig. 4.3). This purity is similar to other 
commercially available porphyrin products tested (Porphyrin Products, Logan Utah, USA). 
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PEA 
HPPEEA 
Figure 4.l. Molecular structure of pheophorbide a ethanolamide (PEA) and 
hematoporphyrin propyl ether ethanolamide (HPPEEA). 
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Figure 4.2. HPLC chromatogram of methyl pheophorbide a (mPheo). Peaks were 
detected by absorption at 405 nm, reported in relative units (left scale). The peak at 
7.2 min is due to mPheo. 
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Figure 4.3. HPLC chromatogram of PEA. Peaks were detected by absorption at 405 nm, 
reported in relative units (left scale). The peak at 1.7 min is due to PEA. The trace 
contamination indicated by the peak at 3.8 min accounts for 5% of the peak total area, 
indicating that PEA is has 95% purity. 
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4.5 Molecular structure of PEA 
4.5.1 Electronic absorption spectroscopy 
The porphin ring must remain intact during the modification of the basic ChI a 
structure for the characteristic far red absorbance of these chlorins to be maintained. 
Fig. 4.4 shows the absorption, excitation, and emission spectra of mPheo. The high 
absorption of the first Q band at 665 nm indicates that the porphin ring is still intact. The 
similarity of the absorption and excitation spectra further indicates that a single molecular 
species is responsible for the fluorescence . The molar extinction coefficients for the Soret 
(413 nm) and the first Q band (667 nm) are 6.25 x 104 M-l cm-l and 2.80 x 104 M-l cm-\ 
respectively . The ratio of the Soret to the first Q band is 2.23 which is similar to that 
reported by Pennington et al. (1964) . 
The absorption spectrum of PEA has the shape of a typical chlorin type spectrum 
(Spikes, 1990), with a high absorption of the first Q band at 665 nm (Fig. 4.5). Again, 
the similarity of the fluorescence excitation spectrum and the absorption spectrum 
indicates only one fluorescent species. The molar extinction coefficients for the Soret 
(405 nm) and first Q band (665 nm) are 7.94 x 104 M-l cm-l and 2.64 x 104 M-l cm-l 
respectively . The molar extinction coefficient ratios of the respective bands (mPheo/PEA) 
are: Soret; 0.79 and first Q band; l.06. The near unity of these ratios again infers that 
the major chlorin chromophore is retained in PEA. The ratio of the Soret to the first Q 
band in PEA is 3.03 , being slightly higher than that for mPheo, due to the higher molar 
extinction coefficient of the Soret band of PEA. 
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Figure 4.4. Absorption, fluorescence excitation, and fluorescence emission spectra of 
methyl pheophorbide a in dichloromethane: pathlength = 1 cm; concentration for 
absorption spectrum = 24.8 ~M; concentration for fluorescence excitation and emission 
spectra = 1.24 ~M; excitation À at 400 nm for emission spectrum; emission À monitored 
for excitation spectrum at 680 nm. Vertical lin es are at 413 nm and 667 nm. 
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Figure 4.5. Absorption, fluorescence excitation, and fluorescence emission spectra of 
PEA in dichloromethane: pathlength = 1 cm; concentration for absorption spectrum = 30.2 
IlM; concentration for fluorescence excitation and emission spectra = 0.604 IlM; excitation 
À at 400 nm for emission spectrum; emission À monitored for excitation spectrum at 680 
nm. Vertical lin es are at 405 nm and 665 nm. 
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4.5.2 IR spech·oscopy 
The presence of the carbonyl ketone, methyl ester, and amide groups of the 
various chlorin derivatives can be monitored by their IR spectra. Fig. 4.6 and 4.7 
represent the FT-IR spectra of mPheo and PEA. Salient features of the mPheo spectrum 
include the strong methyl ester band at 1743 cm-1 and the strong free ketone carbonyl 
band at 1701 cm-1 which are similar to those reported for Chi a by Chapados (1988). 
In the IR spectrum ofPEA, the band at 3307 cm-1 (Fig. 4.7) indicates the presence 
of an NH amide and OH of the amide si de group (Bellamy, 1975). Aiso 1655 cm-1 band 
is the ketone of the amide. The disappearance of the ketone band at 1700 cm-1 in the 
PEA IR spectrum indicates that the free ketone carbonyl at C-9 of ring V has changed. 
This suggests that perhaps ring V has opened and that the ketone is transformed into an 
amide. 
4.5.3 NMR spectroscopy 
The NMR spectra can provide further support for the molecular structures 
indicated by IR spectroscopy. The ethanolamide moiety could be located on the chlorin 
ring in one of two possible locations, either at position 6 or at position 7 (Fig. 4.1) . 
Amino type compounds usually attach to chlorins at ring V (Pennington et al. , 1967; 
Gurinovich et al. , 1992). Ring V of the chlorin would likely be opened if the 
ethanolamide group attaches to position 6, and the ketone carbonyl carbon C-9 would be 
reassigned to C-6a and the peak in the l3C NMR spectrum of PEA would disappear 
(Smith and Unsworth, 1975). Detailed l3C NMR spectra analysis of mPheo has been 
discussed by Smith and Unsworth (1975), who indicate that the free ketone carbonyl 
carbon C-9 on ring V pro duces a peak at 190 ppm. That ketone carbonyl peak is shown 
in the l3C NMR spectra of mPheo (Fig. 4.8). The C-9 ketone carbonyl peak is not present 
in the l3C NMR spectrum of PEA, but the C-6a peak is found at 167 ppm indicating that 
during the reaction forming the ethanolamide, ring V is opened and the free ketone 
carbonyl is changed (Fig. 4.9). To be certain that the 190 ppm peak is not present in 
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Figure 4.8 l3C NMR spectrum of methyl pheophorbide a in deuterated chloroform. Peaks which have assignments are as 
follows: 190, C-9; 173, C-7c; 170, C-10a; 130, C-2a; 124, C-2b; 105.5, C-y; 105, C-I3; 99, C-a; 93, C-Ù; 65, C-10; 53 , C-10b; 
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Figure 4.9. \3C NMR spectrum of pheophorbide a ethanolamide in deuterated chloroform. Peaks which have assignments are 
as follows: 171, C-7c; 170, C-6a; 167, C-yb; 128, C-2a; 122, C-2b; 102.2, C-y; 102, C-l3; 99, C-a; 94, C-8; 62, C-6c 
(CH20H); 52, C-yc; 5l.5, C-7d; 51 , C-7; 49.9, C-8 ; 43 , C-6b (NH-CH2) ; 38, C-ya; 23 , C-8a; 20, C-4a; 19, C-4b; 13, C-1a; 
Il , C-3a. Note that the ketone carbonyl peak of C-9 on ring V of the porphin is not observed at 190 ppm. 
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PEA its l3C spectrum, shown in Fig. 4.9, was collected for several days. Pandey et al. 
(1991), who synthesized several chi orins whi ch had opened ring V, found that when ring 
V was opened with the 5 % H2S04 in methanol a methyl ester was attached at position 
C-6, and a strong methyl ester proton peak was observed at 4.25 ppm in the proton NMR. 
That 4.25 ppm peak is not observed in the proton NMR of PEA, further supporting that 
the ethanolamide was located at position C-6 on PEA. The singlet (6 .2 ppm) from lO-H 
in proton NMR of mPheo (Fig. 4.10) is not observed in PEA, however a double doublet 
(5 .5 ppm and 4.75 ppm) from ya-H2 is observed in PEA (Fig. 4.11). In the proton NMR 
spectrum of PEA, the hydrogen on the NH of the amide at 6.8 ppm is identified (Fig. 
4.11). This amide peak is not present in the proton NMR spectrum of mPheo (Fig. 4.10). 
A single hydrogen is indicated by the NH 6.8 ppm peak confirming that only one 
ethanolamide has attached to PEA. Thus the structure of PEA is believed to be as shown 
in Fig. 4.1 (pg 59) and 4.12 (pg 73). 
4.6 Biological evaluation of new dual action drugs 
4.6.1 Acute toxicity of the ethanolamides 
Both HPPEEA and PEA were found to have low acute toxicity in a mouse model. 
No toxicity was observed after three daily injections of 166 mg kg-l body weight of PEA, 
for a total of 500 mg kg-l administered. No toxicity was observed after seven daily 
injections of 100 mg kg-l body weight of HPPEEA for a total of 700 mg kg-l 
administered. In both drugs the high dose had to be administered over several days due 
to the limited drug solubility in an injectable solution. No LDso values can be quoted for 
either drug Slllce at the doses administered no toxicity was apparent. 
Polyhematoporphyrin gave an LDso of about 150 mg kg- l . 
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Figure 4.10 Proton NMR spectrum of methyl pheophorbide a in deuterated chloroform. Peaks which have assignments are 
as follows: 9.45, 1H, a-H, s; 9.32, 1H, B-H, s; 8.5, 1H, 8-H, s; 7.9, 1H, 2a-H, dd, j=13Hz, j=22 Hz; 6.2, 2H, 2b-H, dd, j=12 
Hz, j=17 Hz; 6.2, 1H, 10-H, s; 4.46, 1H, 8-H, d, j=8; 4.20, 1H, 7-H, d, j=8; 3.8, 3H, 10-COOCH3, s; 3.65, 2H, 4a-H2, q; 3.65, 
3H, 7-COOCH3, s; 3.65, 3.35, 3.19, 3H x 3, ring 1,3,5- CH3, s; 2.6, 2H, 7a-H 7b-H; 2.25, 2H, 7a'-H 7b'-H; 1.8, 3H, 8-CH3, 
d, j=9 Hz; 1.2, 3H, 4b-CH3, t, j=7 Hz; -1.7, 2H, ring N-H, s. 
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Figure 4.11 Proton NMR spectrum of pheophorbide a ethanolamide in deuterated chloroform. Peaks which have assignments 
are as follows: 9.62, 1H, a-H, s; 9.60, 1H, J3-H, s; 8.8, 1H, 8-H, s; 8.1, 2a-H, dd, j=12 Hz, j=19 Hz; 6.8, 1H, 6-NH, t, j=5 Hz; 
6.35 & 6.15, 2H, 2b-H2, d & d, j=18 & 13 Hz; 5.5 & 4.75, 2H, ya-H2, d & d, j=19 & 19 Hz; 4.45, 1H, 8-H, d, j=8 Hz; 4.38, 
1H, 7-H, d, j=8 Hz; 3.7, 3H, y-COOCH3, s; 3.7, 2H, 4a-H2, q; 3.6, 3H, 7-COOCH3, s; 3.5, 3.5, 3.3, 3H x 3, ring 1,3,5-CH3, s; 
2.45, 2H, 7a-H & 7b-H; 2.2, 2H, 7a'-H & 7b'-H; 1.6, 3H, 8a-CH3, d, j=9 Hz; 1.2, 3H, 4b-CH3, t, j=7 Hz; -1.8, 2H, ring NH, s. --.l 
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Figure 4 .12. Proposed molecular structure of PEA. (A) Structural drawing, (B) space 
filling molecule viewed from above the plane of the porphin ring, (C) space filling 
molecule viewed from the edge (perpendicular to the plane) . Space filling molecular 
configurations were generated by Desktop molecular modeller (ver. 2.0, Oxford university 
press, 1991). 
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4.6.2 Chemotherapy 
4.6.2.1 MTT assay 
The MTT assay tests the cytotoxic actIvlty of cytotoxic compounds toward 
neoplastic cell lines by measuring spectroscopically the amount of blue formazan dye 
produced by surviving cells. Various hum an neoplastic cell lines were tested to evaluate 
the chemotherapeutic activity of the ethanolamide derivatives HPPEEA, PEA and their 
parent compounds, HPIX and mPheo from which they were synthesized. A weIl known 
chemotherapeutic drug, adriamycin, was used as a positive control, while the PDT drug 
pHP was used as a negative control. 
The survival curves are shown in Fig. 4.13 to 4.18. In these curves the cell 
survival is expressed as a percent, compared with the blank untreated control cells which 
received no drug treatment, such that 100% survival refers to no cytotoxicity. The data 
for each survival curve is provided in an attached table (Table 4.1 to 4.6). Generally in 
any single experiment all the cell lines responded similarly to a particular drug. 
For adriamycin, cytotoxicity began to be manifested in the cell lin es at 0.01 J.lM 
and by 100 J.lM there was near 0% survival (Fig. 4.13 and Table 4.1). 
For pHP, the negative control , sorne cytotoxicity was observed in the celllines at 
about 50 J.lM and at the highest concentration (100 J.lM) the response was about 20-60% 
cell survival (Fig. 4.14 and Table 4.2). 
HPIX (the parent compound of HPPEEA) exhibited very little cytotoxic activity. 
At the highest HPIX concentration tested (100 J.lM) sorne cytotoxicity was observed in 
the celllines (Fig. 4.15 and Table 4.3), for example, 30% survival for the cellline K562. 
HPPEEA exhibited significant cytotoxic activity . When 20 J.lM of HPPEEA was 
added the cell survival dropped to near 10% (Fig. 4.16 and Table 4.4). Below 20 J.lM, 
little cytotoxicity is observed. 
Methyl pheophorbide showed very little if any cytotoxicity. At the highest 
concentration of mPheo tested (100 J.lM) cell survival was still approximately at 80% (Fig. 
4.17 and Table 4.5). 
PEA showed less than 10% cell survival at 40 J.lM indicating a similar response 
to HPPEEA, but at a higher concentration (Fig. 4.18). 
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Figure 4.13 . Cell survival curves for adriamycin treated cells in the MTT assay. Survival 
expressed as a percent of the control untreated cells. 
Table 4.l. Percent cell survival of vanous neoplastic cell lines at vanous IlM 
concentrai ons of adriamycin. 
Concentration SIHA K562 RAJI Hela H69 H209 2780.9S MDA.MD 
0.00174 80.7±35.4 105 .7± 11.7 98.7±5.1 68.1 ±3.5 90 .8±5.5 86 .0±6.2 85 .5 
0.01 115.5±23.9 110.0±23.9 97.5±9.7 86.5±13 .5 85 .6±14.0 107 .6±14.2 121.3±16.9 
0.0174 84.7±19.9 82.3±27.7 88.4±0.4 88.7±48.4 68 .0±3.0 86.7±1.5 87 .5 
0.1 72.2±16.3 100.1±25.8 105 .6± 14.3 81.4±13 .3 82.2± 16.7 85 .6±17 .1 105.4±12.0 96.8±12 .9 
0.174 80.9±25 .0 52.0±28.7 80.9±3.5 32.9±12.1 21.5±6.8 84.l±1.5 78 .1 
21.0±12 .5 60.8±37.9 55.9±31.5 59.6±34.4 71.9±20.9 56.9±30.9 92.3±9.9 64 .0±28.2 
1.74 21.6±22 .1 20.8±12.4 32 .1± 19.2 19.7±6.0 17.9±8.6 92.6±5.1 49.7 
10 4.4±2.8 22.1±8.5 8.6±6.0 20.2±24.2 37 .71±23 .2 23.l±18 .7 56.9±24 .5 50.48±29.2 
17.4 10.6±9.6 15 .5±17 .0 4.8±0.5 7.4±2.5 7.9±2.8 28.0±7.4 6.2 
50 3.5±1.9 9.5±6.3 2.5±2.9 7.0±4.7 16.8±16.4 5.8±2.9 13 .8± 16.8 11.8±10.2 
100 7.5 1.1 6.1 6.6 1.5 7.4 5.0 
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Figure 4.14. Cell survival curves for polyhematoporphyrin treated cells in the MTT assay. 
Survival expressed as a percent of the control untreated cells. 
Table 4.2. Percent cell survival of vanous neoplastic cell hnes at vanous /-lM 
concentraions of polyhematoporphyrin. 
Concentration 8IHA K562 RAJI Hela H69 H209 2780.98 MDA.MD 
0.00167 68.8 95.2 78 .0 61.6 94.6 88.5 92.8 
0.0167 68.8 9l.3 90.6 83.6 91.1 90.7 84.4 
0.1 99.1 91.5 93.9 95.7 91.2 88.9 97 .0 
0.167 70.6 93.8 87 .8 55.7 94.6 83.2 81.8 
97.1±13.0 94.9±9.0 103.9±11.8 87 .3±5.8 84 .9±7.8 95.7±8.9 92.8±8.8 95.4±0.2 
1.67 69.4 97.4 97.4 60.2 93.8 96.6 81.1 
10 97.0±1 1.7 100.2±3.0 lO2.4±O.7 82.6±24.7 81.4±7.7 101.0±11.8 lOl.O±11.7 103.5±5.8 
16 .7 63 .8 60 .1 6l.3 54.2 77.8 96.0 88.4 
50 89.9± 16.7 58.4± 17 .1 54.2±3.4 52.6±25 .8 70.0±1.1 65.7 60 .0±0.5 92.5±22.5 
100 69.4±34.4 14.3 17.7±8.4 15.6±7.6 29.0±13.7 53.7±26.6 18.1±1.0 44.2±10.6 
120 
-..:.-- SIHA 77 
-K562 
--<>-- RA.J 1 
100 --HELA 
--0-- H69 
--2780.9S 
-as -+-- MDA.MB 
::> 80 
-> 
-~ 
c:r.J 
--
60 
c= 
CI> 
<..> 
-CI> 40 II:L 
20 
0 
.001 .01 .1 1 10 100 
Concentration (J.JM) 
Figure 4.15. Cell survival curves for hematoporphyrin treated cells in the MTT assay. 
Survival expressed as a percent of the control untreated cells. 
Table 4.3. Percent cell survival of vanous neoplastic cell lin es at vanous !lM 
concentraions of hematoporphyrin. 
Concentration SIHA K562 RAJI Hela H69 H209 2780.9S MDA.MD 
0.00149 100.3 93 .5 71.5 69 .2 88.9 88.8 86.6 
0.0149 90.8 103.4 76.1 63.4 97.5 82.4 83.1 
0.1 68.7 92.1 85.8 92 .2 91.4 102.4 135 .7 
0.149 99.6 111.8 72 .9 83 .1 98.3 89.1 86.2 
92.2±5.2 82.7±13.3 89.6±15 .9 102.6±24.3 104.8±16.4 94 .0± 14.7 82.5±15.3 115.4±50.5 
1.49 104.4 119.3 84.3 72.2 116.3 108.5 106.9 
10 81.6±9.3 82 .5±9.1 7l.4±24.1 113.0±25 .6 104.1±12 .3 99.5±13 .9 75 .5±28.8 103 .8±27.2 
14.9 17.3 65.4 12.6 21.9 18.5 85.9 106.2 
50 52.6±7.7 55 .9±13.4 27.6±14.7 109.1±5.9 82 .9±6.2 93 .3±3.3 81.4±22 .7 107.3±34.0 
100 44.5±18.9 32.1±23.4 17.0±4.6 104.4±35 .0 62.6±1.3 84.6±1.2 43 .8±37.4 82.8 
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Figure 4.16. Cell survival curves for HPPEEA treated cells in the MTT assay. Survival 
expressed as a percent of the control untreated cells. 
Table 4.4. Percent cell survival of vanous neoplastic cell lin es at vanous J-lM 
concentrai ons of HPPEEA. 
Concentration SIHA K562 RAJI Hela H69 H209 2780.9S MDA.MD 
0.00157 95 .7 95 .9 100.5 92 .5 85 .4 86.6 90.0 
0.0157 98.2 98.2 105.1 101.1 82.2 76.0 92 .0 
0.1 72.9 96.1 99.6 95.5 97.8 106.4 137.4 
1.157 9l.l 105 .6 87.0 73 .8 67 .9 87.5 85 .5 
100.4±13.4 84 .7±9.2 99.5±7.0 118.7±22 .9 97.0±19 .8 104 .9±5.2 100.2±0.2 112.0±33 .1 
1.57 97.5 87.8 101.8 95 .9 68.1 92 .7 50.2 
10 114.2±21.2 87.6±4.5 92 .0±6.7 107 .7± 14.6 109.5± 14.0 99.2±13.3 59 .9±20.1 71.3±37.8 
15.7 28.5 23 .6 7 .8 17.1 16.1 19.3 24.3 
50 2.2±1.4 5.7±0.5 5.9±3.0 7.4±2.5 16.1±1.5 8.6±5.1 12.3±4.0 7.4±4.7 
100 6.7±3.5 6.6±0.7 5.4±0.9 10.5±7.1 14.4±1.3 9.8±5.9 6.5±1.6 5.2±0.1 
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Figure 4.17. Cell survival curves for methyl pheophorbide a treated cells in the MTT 
assay. Survival expressed as a percent of the control untreated cells. 
Table 4.5. Percent cell survival of vanous neoplastic cell lin es at vanous !lM 
concentraions of methyl pheophorbide a. 
Concentration S!HA K562 RAJ! Hela H69 H209 2780.9S MDA.MD 
0.00167 97.2 106.4 73.0 99.1 89.7 79.7 88.5 
0.0167 97.4 10004 71.8 94.1 85.9 74.5 86.8 
0.1 86.0 92.9 89.1 70.7 83.6 100.0 128.2 
0.167 94 .7 104 .0 84.0 83 .5 83 .0 72.2 89.2 
98.0±504 93.3±1.4 101.8±17.9 7704±8.5 84.3±2.6 90.2±804 94.9±4.3 11504±31.1 
1.67 101.2 104.7 82.7 89.1 94.0 77.8 48 .9 
10 90.8±11.1 97.3±3.1 106 .7±7.6 72 .1±3.6 79.0±8.6 91.7±2.1 9304±6.2 103.3±16.1 
16 .7 99.7 108.5 85 .1 80.9 92 .3 85 .6 9004 
50 81.0± 10.0 97.3 10604±7.8 48.7±26.7 76 .7±12.2 85.2±1.8 90.1±19.9 101.3±15 .8 
100 68.0±8.1 105.7±15 .0 94 .3±1.1 36 .7±34.1 63 .6±12.9 82.3±3.7 83.2±1004 68 .9 
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Figure 4.18 . Cell survival curves for PEA treated cells in the MTT assay. Survival 
expressed as a percent of the control untreated cells. 
Table 4.6. Percent cell survival of vanous neoplastic cell lines at vanous J.lM 
concentraions of PEA. 
Concentration SIHA K562 RAJ! Hela H69 H209 2780.9S MDA.MD 
0.1 129 .4 117.9 126.0 95.7 101.9 98.8 109.8 
97.8±5.6 112.6±24.8 119.0±8.0 113.6±57.0 101.3±10.5 102.0±10.2 117.0±7.1 120.7±16.8 
10 99 .9±8.6 115.2±28.9 120.6±0.1 112 .6±51.7 98.4±14 .8 106.0±1.0 99.0±9.7 107.4±13.0 
50 1.2±1.0 6.1±3.4 2.5±3.1 6.3±4.1 58.7±7.9 59.4±25.5 1.7±1.l 1.6±0.9 
100 1.l±0.7 2.9±3.0 3.3±4.5 7.8±8.9 14.4± 12.3 5.2±4.2 1.7±0.4 1.6±0.4 
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The cytotoxic activity ofboth ethanolamide compounds occurred over a very small 
concentration range compared to adriamycin. The ethanolamide compounds had no effect 
at 10 !lM and caused almost 100% cell death by 20-40 !lM (Fig. 4.16 and 4.18). 
For a comparison of the response of the different cell lines to the various drugs 
tested, the IC5o, or drug concentration required to cause a 50% survival, was examined 
(Fig. 4.19, 4.20 and Table 4.7). From these two figures, it is apparent that the 
ethanolamides can exhibit sorne cytotoxic activity at a higher concentration than that of 
adriamycin. It is also apparent from Fig. 4.19, 4.20 and Table 4.7 (cell lines 2780.9S; 
MDA.MB; H69) that PEA requires about twice the concentration of HPPEEA to 
accomplish the 50% cell kill in sorne of the cell lines, while the parent compounds of the 
ethanolamides, and pHP, had very little cytotoxic activity. 
Table 4.7. Summary of the concentrationsR derived from MTT cytotoxicity assay required 
to obtain an IC5o. 
CeUlines Adriamycin pHP HP IX HPPEEA rnPheo PEA 
2780.9S 15±1 65±7 >1 00 16±8 >100 35±7 
Daudi 0.3±0.2 28±4 15±5 22±6 25 35±7 
H69 3±3 75±7 70±52 22±6 >100 55±7 
Hela 2±1 73±39 71±50 21±6 25 35±7 
K562 1±1 75±35 44±29 22±6 >100 35±7 
MDA.MB 9±1 85±21 >100 12±1 2 >100 35±7 
Raji 2±1 60±14 57±40 21±6 >100 35±7 
SIHA 0.5±0.3 95±6 56±12 44±1 8 >100 35 
(a) AU concentrations values are in !lM. 
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Figure 4.19. ICso of various cytotoxic agents on several human neoplastic cell lines: 
Part 1. 
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Figure 4.20. ICso of various cytotoxic agents on severa! human neop!astic cell lines: 
Part 2. 
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4.6.2.2 Animal tumour studies 
The MTT assay is useful for the preliminary evaluation of cytotoxicity, but it is 
necessary to investigate the entire living systems in order to assess anti-cancer drug 
response of tissues. This can be achieved using animal models which have implanted 
tumours. For these tests, two cancer types were used, the solid tumour Lewis lung 
carcinoma and the ascites leukemia cancer P388, representing both localized and non-
localized forms of cancer respectively. 
4.6.2.2.1 Lewis lung carcinoma in C57BL6 mice 
The growth progression of the Lewis lung carcinoma in C57BL6 mi ce is illustrated 
in Fig. 4.2l. The control animais, which received no drug, died at 8 to 10 days with 
small tumour diameters (about 15 mm) (Fig. 4.21). Numerous secondary tumours were 
observed in many anatomical locations when the control animais were examined, by 
dissection after death. 
The animais treated with either HPPEEA or PEA (10 mg kg-l) survived up to 25 
days, which is an increase of over 100% in "Time to death" (TD). The primary tumour 
did not stop growing when subjected to either HPPEEA or PEA. Unlike a study using 
adriamycin at 7 mg kg-1 where 80% of the primary tumours were stopped (Corbett et al., 
1984). However, in this study no secondary tumours were observed when the animais 
were examined after death. The results thus indicate that under these study conditions 
treatment with the ethanolamide drugs appeared to prevent secondary tumours, but does 
not stop the primary tumour. The prevention of secondary tumours suggests that 
metastasis was stopped by intervention from the ethanolamide derivatives. 
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Figure 4.21 . Chemotherapeutic treatment of the solid tumour Lewis lung carcinoma in 
C57BL6 mi ce, with HPPEEA and PEA at a dose of 10 mg kg-1 daily IP. Control animaIs 
received injection solvent only. Each point represents the tumour diameter of a single 
animal with the different symbols representing individual mice. The time of death (TD) 
for each mouse is at the last corresponding time point. 
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4.6.2.2.2 Ascites leukemia P388 in B6D2F 1 mice 
To test the hypothesis that the ethanolamide derivatives can prevent metastasis, the 
chemotherapeutic activity of the ethanolamides was evaluated using the metastatic cancer, 
leukemia (P388), that does not form a distinct solid tumour. The progression of this 
cancer can be evaluated by the animal's weight gain expressed as a percent of the original 
weight. The control animaIs showed a 20-30% increase in weight at death, occurring in 
about 8 days (Fig. 4.22). No increase in TD in HPPEEA treated animaIs, and only a 
slight TD increase in PEA treated animaIs, was observed, indicating that the cancer 
response to the ethanolamides (dose = 10 mg kg-1) was minimal (Fig. 4.22). 
Another experiment was performed using a higher drug concentration, since the 
MTT cytotoxicity test had indicated that the IC50 of the ethanolamides were ~22 J..lM for 
HPPEEA and ~35 J..lM for PEA (Table 4.7 in section 4.6.2.1). The higher dose used was 
100 mg kg-\ which is 10 times the previous dose. The results (Fig. 4.23) were similar 
to the previous P388 experiment indicating a slight increase in TD compared to the 
controls. However, a notable lag before commencement of animal weight gain, of several 
days, was observed in both experimental trials where the animaIs were treated with 
ethanolamides. 
4.6.3 Pharmacokinetics 
A new PDT drug must demonstrate selective retention in neoplastic tissues, and 
have relatively low accumulation in the skin in order to be clinically useful. The tissue 
selectivity of PDT drugs is evaluated by their tissue pharmacokinetics by the means of 
fluorescence intensity measurements. The pharmacokinetic data for HPPEEA and PEA 
have been separated into three categories: i) serum measurements; ii) in vivo 
measurements; and iii) ex vivo measurements. 
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Figure 4.22. Chemotherapeutic treatment of leukemia P388 in B6D2F1 mice with 
HPPEEA and PEA at a dose of 10 mg kg-1 daily IP. Control animaIs received injection 
solvent only. Each line represents the percent weight variation after cancer implantation 
of a single animal with the different symbols representing individual measurements. The 
time of death (TD) for each mouse is at the last time point. 
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Figure 4.23. Chemotherapeutic treatment of leukemia P388 in B6D2F1 mice with 
HPPEEA and PEA at a dose of 100 mg kg,1 daily IP. Control animaIs received injection 
solvent only. Each line represents the percent weight variation after cancer implantation 
of a single animal with the different symbols represent individual measurements. The 
time of death (TD) for each mouse is at the Iast time point. 
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4.6.3.1 Serum measurements 
The serum clearance curve of HPPEEA and PEA are presented in Fig. 4.24. Both 
the HPPEEA and PEA concentration in the serum retumed to background levels by about 
30 h post IP injection (injection solvent formulation was DMSO/human serum in a 10/90 
(v/v) ratio). The peak HPPEEA concentrations measured in serum (2800 ng mL·l ) were 
comparable to those reported for other PDT drugs (Biolo et al., 1991). However, the PEA 
concentration measured in the serum was low. The curve profile was typical but the peak 
drug concentration measured (75 ng mL· l ) was lower than expected of a typical 
photosensitizer by a factor of almost 40. These have been confirmed by another series 
of measurements. 
The fluorescence signal measured from several concentrations of PEA was the 
same with and without serum in the solvent, indicating that the serum was not quenching 
the fluorescence signal of PEA. 
4.6.3.2 In vivo measurements 
The in vivo pharmacokinetic data for HPPEEA in mlce bearing Lewis lung 
carcinoma is shown in Fig. 4.25 . HPPEEA fluorescence had decreased to background in 
an tissues by about 24 h. No significant selectivity is apparent in any tissue. 
The in vivo pharmacokinetics of mPheo in mice bearing Lewis lung carcinoma is 
shown in Fig. 4.26. Methyl pheophorbide a cleared from the thigh and tumour sites 
rather quickly, reaching background levels at around 10 h. The skin and abdomen sites 
indicated a slower clearance, reaching background fluorescent levels at around 25 h. 
The clearance (about 25 h) of PEA from tissues measured by in vivo 
pharmacokinetics was similar to mPheo (Fig. 4.27). 
The in vivo clearance curves of tissue sites can not be compared to each other due 
to different fluorescence characteristics of each site. Also, tissue sites of different studies 
should not be compared sin ce the instrumentation is standardized within each experiment 
but not between experiments. The main focus of the in vivo pharmacokinetics is to 
determine within a single animal the clearance of a drug from various tissues. 
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Figure 4.24. Serum pharmacokinetics of HPPEEA and PEA in B6D2F1 mlce, 
administered a single IP injection of 10 mg kg-l of the drug. At various time points the 
animaIs were killed and the blood was removed by cardiac puncture. The serum was 
separated from the blood, and drug concentrations were measured by fluorescence. Each 
point represents at least three animaIs and has an error of less than 20%. 
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Figure 4.25 . In vivo pharmacokinetics of HPPEEA (dose = 10 mg kg-l) in SKH-HR1 
mi ce bearing Lewis lung carcinoma. Curves are expressed as fluorescence intensity 
relative to a standard solution of uroporphyrin. The maximum error on any individual 
datum point is 20%. 
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Figure 4.26. In vivo pharmacokinetics of methyl pheophorbide a (dose = 10 mg kg"l) in 
SKH-HR1 mice bearing Lewis lung carcinoma. Curves are expressed as fluorescence 
intensity relative to a standard solution of uroporphyrin. The maximum error on any 
individual datum point is 20%. 
Figure 4.27. In vivo pharmacokinetics of PEA (dose = 10 mg kg"l) in SKH-HRI mice 
bearing Lewis lung carcinoma. Curves are expressed as fluorescence intensity relative 
to a standard solution of uroporphyrin. The maximum error on any individual datum 
point is 20%. 
93 
4.6.3.3 Ex vivo measurements 
The ex vivo tissue pharmacokinetics of HPPEEA in mice bearing Lewis lung 
carcinoma measured by drug fluorescence intensity is shown in Fig. 4.28. The drug 
fluorescence was the highest in the skin foUowed by kidney, liver, tumour, and muscle, 
and the lowest in the brain. The drug fluorescence had returned to background intensity 
in aU tissues after 25 to 30 h. 
The tissue pharmacokinetics of PEA in mice bearing Lewis lung carcinoma is 
shown in Fig. 4.29. The drug fluorescence was the highest in the skin foUowed by the 
liver, kidney, muscle, and tumour, and the lowest in the brain. PEA fluorescence was at 
background intensity in aU tissues by about 25 to 30 h. 
The tissue pharmacokinetics of PEA was also studied using another animal tumour 
model (Balb c mice bearing a lung carcinoma M4898) (Fig. 4.30). In this experiment 
PEA was at background levels by 24 h. The drug fluorescence was the highest in the 
skin foUowed by the tumour, liver and muscle. There was a marked selective 
accumulation of PEA in the tumour at 3 h post injection relative to the skin or muscle 
(tumour/muscle = 6, tumour/skin = 2). 
4.6.4 Photosensitization activity measured by photohemolysis 
The ethanolamide photosensitization activity . was evaluated by photohemolysis. 
In the photohemolysis assay the amount of hemoglobin released from damaged red blood 
ceUs as a result of photosensitization is measured. The concentrations of drugs used in 
the assay were comparable to those typicaUy measured in tissues by pharmacokinetics. 
The percentage of hemolysis as a function of drug concentration is presented in 
Fig. 4.31 to 4.36. The hemolysis from the solvent alone was always less than 14% (Fig. 
4.31). The no light control in each test indicates that the drug alone had no effect on the 
hemolysis of the red blood ceUs, with the possible exception of PEA where a smaU 
increase is noticable (Fig. 4.35). At the maximum concentration, the % hemolysis is 
17%, slightly higher than the control. 
94 
12 
8 Brain 
4 
12 
8 Kldney 
4 
~ 12 
-CI) 
8 c: 
.! 4 c: 
Uver 
-~ 12 
c: 
i 8 4 Muscle 
0 
:l 12 
-LI.. 
8 Sldn 
4 
12 
8 Tumour 
4 
0 
0 10 20 30 40 50 
Tlme post Injection (h) 
Figure 4.28 . Ex vivo pharmacokinetics of HPPEEA (dose = 10 mg kg-1) in SKH-HR1 
mice bearing Lewis lung carcinoma. Curves are expressed as fluorescence intensity 
relative to a standard solution of uroporphyrin. The maximum error on any individual 
datum point is 15%. 
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Figure 4.29. Ex vivo pharmacokinetics of PEA (dose = 10 mg kg-)) in SKH-HR1 mice 
bearing Lewis lung carcinoma. Curves are expressed as fluorescence intensity relative 
to a standard solution of uroporphyrin . The maximum error on any individual datum 
point is 15%. 
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Figure 4.30. Ex vivo pharmacokinetics of PEA (dose = 10 mg kg-1) in Balh c mice 
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Figure 4.31 . Percent photohemolysis of red blood cells measured at the solvent volumes 
used for testing the potential photosensitizers. Relative hemoglobin concentrations were 
measured by absorption at 414 nm. 
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Figure 4.32. Percent photohemolysis measured for HPIX treated red blood cells with 
varying drug concentrations and light doses. Relative hemoglobin concentrations were 
measured by absorption at 414 nm. 
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Figure 4.33 . Percent photohemolysis measured for HPPEEA treated red blood cells with 
varying drug concentrations and light doses. Relative hemoglobin concentrations were 
measured by absorption at 414 nm. 
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Figure 4.34. Percent photohemolysis measured for methyl pheophorbide a treated red 
blood cells with varying drug concentrations and light doses. Relative hemoglobin 
concentrations were measured by absorption at 414 nm. 
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Figure 4.35 . Percent photohemolysis measured for PEA treated red blood cells with 
varying drug concentrations and light doses. Relative hemoglobin concentrations were 
measured by absorption at 414 nm. 
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Figure 4.36. Percent photohemolysis measured for polyhematoporphyrin treated red blood 
cells with varying drug concentrations and light doses. Relative hemoglobin 
concentrations were measured by absorption at 414 nm. 
103 
HPIX produced 100% hemolysis at a concentration of about 375 nM with a 10 
min light exposure (Fig. 4.32). 
HPPEEA produced 100% photohemolysis at a concentration of 125 nM and a 10 
min light exposure, indicated 3 times higher photohemolytic activity then HPIX (Fig. 
4.33). 
Methyl pheophorbide a had very little photohemolytic activity (Fig. 4.34). At the 
highest mPheo concentrations tested (520 nM), only 18% photohemolysis was observed. 
This value is almost at background level. 
At about 190 nM, and a 10 min light exposure, PEA caused 100% hemolysis (Fig. 
4.35). The concentration of PEA to pro duce 100% hemolysis with 5 min of light was 
only slightly higher. PEA showed high photohemolytic activity. 
Polyhematoporphyrin at a concentration of about 420 nM (concentration of pHP 
is reported as HPIX equivalents (Delettre et al. , 1991)) was required to produce 100% 
hemolysis with a 10 min light exposure (Fig. 4.36). Polyhematoporphyrin showed lower 
photohemolytic activity than either of the ethanolamide derivatives. 
Table 4.8 is a summary of the photohemolysis data. For this comparison, the drug 
concentration required to produce 50% hemolysis is tabulated. PEA exhibited the highest 
photohemolytic activity, followed by HPPEEA, HPIX, pHP, and lastly mPheo. While 
PEA showed slightly higher activity in the 5 min light exposure both ethanolamides have 
about twice the photohemolytic activity of pHP and higher activity than their parent 
compounds. 
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Table 4.8. Summary of photohemolysis results : concentration of photosensitizer required 
for 50% hemolysis. 
Photosensitizer 
PEA 
HPPEEA 
HPIX 
pHP a 
mPheob 
10 min light 
conc in nM 
80 
90 
170 
190 
> 525 
5 min light 
conc in nM 
140 
210 
460 
300 
>525 
Figures 
4.35 
4.33 
4.32 
4.36 
4.34 
Ca) pHP concentration is reported in HPIX equivalents. The molecular weight of HPIX was used to 
calculate the Molar equivalents of HP IX using the mass weight of pHP (Delettre et al. , 1991). 
(b) On1y a small amount of photohemo1ysis is observed. 
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Chapter 5 Discussion 
5.1 Objectives for the ethanolamide drugs 
For the ethanolamides studied in this project to be useful as dual action anti-cancer 
drugs the proposed requirements were: possible synthesis of gram size quantities, high 
absorption in the far red, high neoplastic tissue selectivity, high photosensitization activity, 
and high chemotherapeutic activity . Large quantities are required for the various 
biological tests used to assess these new drugs. The far red absorption requirement stems 
from the higher light transmittance of far red light through tissues, su ch that more photons 
are available for absorption by the drug at deeper tissue location. High selectivity for 
neoplastic tissue is required in order to restrict the PDT response to only cancerous 
tissues. High photosensitization efficiency is required so that a significant response can 
occur with a minimum amount of light and drug. Chemotherapeutic activity is required 
if such molecules are to be representative of a new class of dual action anti-cancer drugs. 
The newly synthesized drug PEA will be discussed in the following sections based on its 
success at meeting the requirements outlined above. AIso, PEA will be compared to 
HPPEEA for several of the tests as the latter is also a potential member of this new class 
of drugs (Girard, 1992). 
5.2 Synthesis and purity of PEA 
There were five concerns in the synthesis of PEA: i) producing sufficient 
quantities of the final product for biological testing; ii) testing the purity of the final 
product; iii) maintaining the far red absorption as provided by the chlorin ring; iv) 
identification of the number of ethanolamide moieties present and; v) the identification 
of the location on the molecule where the ethanolamide groups(s) attach. The first 
concern is answered by the product yield. The second con cern can be answered by HPLC 
analysis. The third con cern can be answered by an examination of the molecule's 
electronic absorption spectrum; the absorption spectrum of PEA would be significantly 
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different from mPheo, its parent compound, if the chlorin ring had been changed and the 
conjugated ring structure disturbed (Spikes, 1990). The fourth and fifth concerns can be 
answered by examination of the IR and NMR spectra of PEA. The discussion of the 
results in light of these concerns are covered in the following sections. 
5.2.1 Quantity of PEA synthesized 
The synthesis of PEA had to provide sufficient product (typically gram size 
quantities) for biological evaluation. The obtention of sufficient product was a noted 
difficulty with the preliminary chemotherapeutic evaluation of HPPEEA (Girard, 1992). 
Thus it was a goal of this synthesis to produce gram quantities of product. A single batch 
process of ChI a produced typically 0.75 g of mPheo. For 1 g of PEA about 2 g of 
mPheo was required, thus three batch processes of ChI a provided sufficient mPheo to 
synthesize 1 g of PEA. The procedure involved about 1 week of laboratory time. 
Recently, since pheophorbide a has become commercially available in larger quantities 
at competitive prices (Porphyrin Products, Logan, Utah, USA), the procedure to obtain 
PEA may be shortened in future preparations. 
5.2.2 Purity of PEA 
It is desirable for a new synthetic product to be a pure compound; the complex 
mixture Photofrin n® is a clear example (Bonnett and Berenbaum, 1989) of the difficulties 
in evaluating biological response from a mixture. Bonnett and Berenbaum suggest that 
many of the conflicting results in Photofrin n® studies are due to its complex nature. 
PEA was found to contain about 5% impurities (Fig. 4.3) which makes it comparable to 
porphyrin products commercially available. 
5.2.3 Far red absorbance of PEA 
The absorption spectra of mPheo and PEA (Fig. 4.4 and 4.5) are qui te similar. 
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This indicates that the porphin ring of the PEA was not affected during the synthesis 
procedure. The first Q band of PEA has a high molar extinction coefficient of 2.64 x 104 
M-1 cm-1 which is comparable to the value of 2.80 x 104 M- 1 cm-1 for mPheo. These 
values are typical of chlorins (Spikes, 1990). The far red absorption of the chlorins as 
well as the higher far red light transmittance of tissues provides a better opportunity for 
photosensitization in deeper tissues (van Lier, 1988, Spikes, 1990). However, as 
suggested by Dougherty and Potter (1990), if the absorption is very high then optical 
screening can become a problem, such as observed in the phthalocyanines (Henderson, 
1989). The chi orin type photosensitizers provide an intermediate position (Fig. 2.2), 
having higher absorption, further in the red then porphyrins (Spikes, 1990), but not to the 
extent of the phthalocyanines. Thus PEA should have a suitable absorption wavelength 
and efficiency for PDT without a screening effect. 
5.2.4 Number of ethanolamide groups present 
The number of ethanolamide moieties present on PEA could potentially 
affeét its chemotherapeutic activity . PEA has one ethanolamide present, as indicated by 
the amide peak in the proton NMR spectrum for PEA (6.8 ppm) (Fig. 4.10). In 
comparison, the porphyrin ethanolamide HPPEEA contains two ethanolamides groups and 
has an amide peak at 6.7 ppm in the proton NMR spectrum (Girard, 1992). 
5.2.5 Location of the ethanolamide group 
The position of the ethanolamide(s) on the molecule can affect the biological 
activity of PEA. The position of polar groups on a molecule can effect the amphiphilic 
character of that molecules and its tissue localization (Moan et al. , 1987; Moan and Berg, 
1992). For example in the sulfonated phthalocyanines (van Lier and Spikes, 1989), when 
the polar sulfonated groups are adjacent (on one side of a molecule) the molecule has 
amphiphilic character and higher tumour tissue selectivity, whereas if the sulfonates are 
opposite the molecule has poor tissue selectivity. The ethanolamide, also polar, could 
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have a similar affect. It is preferable to have aIl the polar groups located at one end of 
the porphin molecule to increase its amphiphilicity. This is the case for PEA, where the 
ethanolamide is located at position 6, and the two methyl esters are on the side chains at 
positions 7 and y (Figs. 4.1 and 4.12). In Fig. 4.12 the proposed molecular shape ofPEA 
iIlustrates how the methyl esters and the ethanolamide moieties are clustered together at 
one end. 
5.3 Biological evaluation of the ethanolamides 
The biological evaluation of the ethanolamides was divided into four sections: i) 
acute toxicity; ii) chemotherapeutic activity; iii) tissue selectivity and pharmacokinetics; 
and iv) photosensitization activity . 
5.3.1 Acute toxicity of the ethanolamides 
Table 5.1 is a summary of sorne PDT and chemotherapeutic drug LDso toxicity values 
obtained in this study (section 4.6.1) compared with LDso values reported in the literature 
for other selected potential and actual anti-tumour drugs. 
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Table 5.1. LD50 toxicity values for ethanolamide derivatives in comparison to selected 
chemotherapeutic agents and potential PDT photosensitizers. 
Compound Drug LDso Conditions Reference 
type (mg kg-J) 
Chlorin e6 PDT 189 mlce Kostenich et al., 1994 
Chlorin e6 PDT 113 rats Kostenich et al. , 1994 
AISPc PDT >100 IV in rats Tralau et al., 1990 
HpD PDT 275 IP in mice Tralau et al. , 1990 
PlI PDT 130 IP in mice Tralau et al. , 1990 
pHP PDT ~150 IP in mice this vvork (4.6.1) 
HPPEEA Both unknovvnb IP in mice this vvork (4.6.1) 
PEA Both unknovvnc IP in mice this vvork (4.6.1) 
Mechlorethaminea Chemo 1.1 IV in rats Windholz et al., 1983 
Adriamycin Chemo 21.1 IV in mice Windholz et al., 1983 
(a) A commonly used chemotherapeutic nitrogen mustard drug (treatment dose = 0.4 mg kg-l in humans 
CCalabresi and Chabner, 1990)) . (b) >700 as a total of 7 daily injections of 100 mg kg- l Cc) >500 as a 
total of 3 daily injections of 166 mg kg-l 
The determination of the acute toxicity limit of any nevv drug is required before 
it can be administered to a patient, since it indicates the treatment dose upper limit. The 
therapeutic index provides an estimate of the toxic risk involved in a drug treatment 
(Gilman et al., 1990). The therapeutic index is calculated by dividing the LDso 
concentration of a drug by the treatment dose (Gilman et al. , 1990). For example the 
nitrogen mustard mechlorethamine has a poor therapeutic index of 2.75 (treatment dose 
= 0.4 mg kg- J (Calabresi and Chabner, 1990) and LD50 = 1.1 mg kg-J) , vvhich indicates 
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that the toxicity risk is quite high. The typical therapeutic index for PlI would be greater 
than 13 since the treatment doses are typically less than 10 mg kg-I (Marcus, 1992). One 
of the reasons PDT is viewed favourably as a form of chemotherapy is because the 
therapeutic index is higher than other chemotherapeutic treatments. The ethanolamides 
have very low toxicity (Table 5.1), which suggests an even higher therapeutic index than 
other PDT drugs. Specific values of LD50 are not reported for the ethanolamides since 
no treated animaIs died. The therapeutic index can only be estimated as greater than 70 
for HPPEEA and greater than 50 for PEA based on the highest dose tested. 
It should be cautioned that the estimated LD50 values expressed for the 
ethanolamides may be higher than reality, sin ce the drugs were administered over several 
days. AIso, the clearance time of these drugs, as indicated from the pharmacokinetics, 
is about 24 h. At this time it is not known what the actual tissue concentrations of the 
drugs were after the several daily drug injections. 
It is not clear why the ethanolamides have such low toxicity . It can only be 
suggested that they may be in a non-toxic, perhaps bound, form in the tissues. Whatever 
the non-toxic conditions are, they must change in neoplastic ceIls, since the neoplastic cell 
cytotoxicity study did indicate that the ethanolamides were chemotherapeutically active 
in the absence of light. 
5.3.2 Chemotherapeutic activity 
The chemotherapeutic activity of the ethanolamides was tested after the acute 
toxicity of the drugs had been determined. The first chemotherapy test was the 
cytotoxicity of the ethanolamides toward hum an neoplastic ceIllines. A nitrogen mustard 
would have been an ideal positive control for these experiments, but due to their short 
lifetime in vivo (Calabresi and Chabner, 1990), the nitrogen mustards were not a suitable 
positive control. The positive control selected was adriamycin because it also is very 
reactive and does not have the short lifetime of nitrogen mustards. Polyhematoporphyrin 
was used as a negative control , since it has not been reported to have any 
chemotherapeutic activity . Further, pHP is a weIl documented PDT agent (Vernon et al. , 
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1995). The drug concentration required for chemotherapeutic activity must be much 
lower than that which causes acute toxicity or the therapeutic index would be too low for 
practical use (Tibbetts et al. , 1977). For example, the average adriamycin concentration 
causing 50% cytotoxicity in the MTT assay was 4.06 IlM. That concentration can be 
expressed as 2.2 mg L-l (MW of adriamycin is 543 .54) which can be compared to about 
2.2 mg kg-l and the LDso in vivo in mice is 21 .1 mg kg- l thus the therapeutic index is 
equal to about 10. As expected, neither pHP nor both of the parent compounds of the 
ethanolamides, HPIX and mPheo, demonstrated any significant cytotoxicity. The 
ethanolamides were expected to have chemotherapeutic activity, but lower than nitrogen 
mustards, based on the background discussion in section 1. 5.2. It was also predicted that 
a di-ethanolamide such as the porphyrin HPPEEA would have a higher chemotherapeutic 
activity than a mono-ethanolamide such as PEA, based on the reactivities observed for 
mono and di-functional nitrogen mustards (Calabresi and Chabner, 1990). This prediction 
was apparent from the MTT assay results (Figs. 4.1 8, 4.l9, and Table 4.7) where 
HPPEEA had about twofold higher activity than PEA. The doubling of the activity for 
the di-ethanolamide thus lends support to the hypothesis that ethanolamide derivatives of 
both porphyrins and chlorins can act as chemotherapeutic agents with a mechanism of 
action possibly similar to that of the nitrogen mustards. Thus the MTT assay suggests 
that the ethanolamides exhibit chemotherapeutic activity at a concentration lower than that 
which causes acute toxicity in vivo . AIso, as predicted the di-ethanolamide (HPPEEA) 
exhibited higher cytotoxic activity than the mono-ethanolamide (PEA), but the 
ethanolamides were not as cytotoxic as adriamycin. 
The MTT cytotoxicity indicated that the ethanolamides were chemotherapeutically 
active in vitro ; however animal testing was required to evaluate their tissue activity . The 
animaIs tumour model used was the B6D2F1 mice bearing Lewis lung carcinoma. These 
animaIs had been used in other chemotherapeutic studies, however with different tumour 
lin es (Tibbetts et al. , 1977). The dose selected for treatment was 10 mg kg- l, (a typical 
PDT dose) since the ethanolamides were expected to be used in combined treatment 
therapy . It is noteworthy however, that since HPPEEA and PEA have low toxicity, higher 
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doses could have been used for chemotherapy. The observed increase in time to death 
(TD) in the treated animaIs is a typical positive result for chemotherapy studies in animals 
models. The animal survival is often increased but rarely is the cancer stopped (Tibbetts 
et al., 1977). The primary tumour did not stop growing in this study. It is possible that 
the lack of tumour regression was due to the poor tumour selectivity of the ethanolamides 
for that tumour, as was indicated by the pharmacokinetics. It would have also been 
informative if a typical chemotherapeutic drug, such as adriamycin, had been tested in this 
animal model to permit comparison between the different agents. However, animaIs 
studies are frequently difficult with chemotherapeutic drugs since the therapeutic index 
of these drugs is very low (Tibbetts et al. , 1977). The effect of the ethanolamides on a 
primary tumour could be further studied with an animal-tumour model which exhibits 
tumour localization of the ethanolamides, such as the Balb c mice with the lung 
adenocarcinoma studied here. 
The observation of a lack of secondary tumours in the ethanolamide-treated 
animaIs for this first chemotherapy test is worthy of further discussion. It has been 
observed upon dissection, that many animaIs carrying Lewis lung carcinoma have 
secondary tumours that develop within 5 to 8 days from the day when the primary tumour 
was implanted. Previous to this ethanolamide treatment study, no animaIs had survived 
for such an extended time periods. Perhaps, although the ethanolamide did not localize 
in the tumour tissue, the drug was able by sorne unknown mechanism to prevent any 
secondary tumours from forming in other anatomicallocations. This fin ding suggests that 
metastasis had stopped. 
To test the hypothesis that the ethanolamides were preventing metastasis, the 
chemotherapeutic activity was assessed with a metastatic leukemic cancer that does not 
form a distinct solid tumour. The leukemia P388 is a very aggressive cancer. It requires 
only a 10 cell inoculum to be established and causes death in 8-10 days. Treatment of 
this cancer with convention al chemotherapeutic drugs does not stopped the cancer, but 
only increases the TD (Sobrero et al. , 1991). Thus, it was not expected that the 
ethanolamides would stop or kill this leukemia, but that the survival time or TD would 
increase. The little if any increase in TD observed in both tests (Fig. 4.21 and 4.22) on 
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P388 suggests that, at least under these study conditions, the ethanolamides have weak 
chemotherapeutic activity, insufficient to slow an aggressive cancer su ch as the P388, 
even at the higher dose of 100 mg kg-1. This was expected sin ce the ethanolamides were 
not expected to have as high a chemotherapeutic activity as, for example, a nitrogen 
mustard. 
A significant observation in the P3 88 tests was the increased lag in initial weight 
gain (Fig. 4.23). Such a lag phase could possibly indicate that the cancer was responding 
to the treatment, but that after several days the cancer had adapted to overcome the drug, 
or the body had adapted to more effectively eliminate it. Adaptation of carcinoma cell 
lines is not uncommon and has been reported for other chemotherapeutic agents such as 
adriamycin (Ozol and Goldstein, 1994). 
The animal chemotherapeutic studies, as weIl as the MTT assay, indicate that the 
ethanolamides have less chemotherapeutic activity than conventional chemotherapy drugs. 
Response of the primary tumour could not be demonstrated during this study, but it is 
suspected that the poor tumour localization of the ethanolamides may be a limiting factor 
towards the attainment of su ch activity . The prevention of secondary tumours may 
indicate an affect by the ethanolamides on metastasis. However, it was not possible to 
clearly demonstrate an affect on metastasitic cancer with the study of the leukemia P388 . 
Thus the results obtained in these chemotherapeutic studies suggest that the ethanolamides 
may be useful as a chemotherapeutic agent, but not necessarily as a principal treatment. 
It should be noted that chemotherapeutic results from animal models are difficult to apply 
to human studies (Tibbetts et al. , 1977). Further, the ethanolamides may work quite weIl 
as a dual action drug, where the chemotherapeutic action is required to destroy only 
residue neoplastic tissue and not the bulk of the tumour. The potential use of the 
ethanolamides toward the complete destruction of deep seated tumours, such as nodular 
basal cell carcinoma, is promising since tumour recurrence is a major problem of such 
tumours. 
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5.3.3 Pharmacokinetics of the ethanolamides 
The tissue distribution and clearance of a drug can be evaluated by that drug's 
pharmacokinetics. The most common method of estimating a drug's pharmacokinetics is 
with animal-tumour models but the extrapolation from such models is often difficult 
(Tibbett et al., 1977). However, animal models are still the easiest subj ects to study and 
are the best approximations available. Thus, the pharmacokinetics results reported here 
are based on mouse-tumour models which were the best available. 
In vivo studies are somewhat limited in usefulness for localization studies unless 
there is a significant accumulation in a tissue. The ex vivo investigations permitted the 
tissue selectivity of the ethanolamides to be evaluated. However this procedure requires 
the use of many animaIs and is rather time consuming. It was thus necessary to 
investigate both in vivo and ex vivo procedures in order to obtain a more complete picture 
of the pharmacokinetics behaviour of the ethanolamides. 
The serum is generally the main carrier of PDT drug to and from tissues if the 
drug is administered IV or IP. The drug is often carried bound by a protein fraction in 
the serum (Rosenberger, 1993). The drug selectivity toward different tissues is often 
affected by the blood fraction to which the drug is bound (Jori, 1992; Hamblin and 
Newman, 1994). For this reason the solvent formula selected for the ethanolamides was 
a serum based formulation which would contain blood proteins. 
The results of the serum pharmacokinetics for HPPEEA, were typical of other PDT 
drugs as given by Biolo et al. (1990) with a similar clearance curve (Fig. 4.24). The 
results observed for PEA serum pharmacokinetics are not as clearly understood. The 
serum clearance curve profile was typical (Fig. 4.24), but the total concentration of PEA 
was about a factor of almost 40 times lower than that of HPPEEA. Even with the low 
serum levels of PEA, the tissues that were measured had typical drug concentrations as 
seen in the ex vivo study (Fig. 4.29). There are no indications in the literature of a 
similar observed low serum concentration of a PDT drug and typical tissues levels. The 
concentrations of PEA in the serum were derived from fluorescence intensity 
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measurements and it was originally thought that the fluorescence of PEA may have been 
quenched in sorne manner by the serum. However, the fluorescence was unaffected at 
several PEA concentrations which were measured with and without serum, indicating that 
the serum was not affecting the fluorescence signal. There are at least two other possible 
explanation for the low serum levels of PEA: i) PEA may have localized into body 
tissues such as the liver before the first time point measured at 1 h so that the serum 
levels were already decreasing; or ii) PEA may be transported in the circulatory system 
by sorne means other than the serum. 
The in vivo pharmacokinetics provide a rapid qualitative method to follow the drug 
clearance and determine total clearance times by monitoring the drug fluorescence. 
However, it is difficult to assess individual tissue selectivity from the in vivo 
pharmacokinetics results due to the composite fluorescence signal source (Biolo et al. , 
1990). The composite fluorescence signal measured from any given site can originate 
from several tissues. Attempts to account for the in vivo fluorescence by a summation 
of the different possible sources has to date not been very successful (Biolo et al , 1990). 
The in vivo pharmacokinetics can provide information on localization within a tissue (if 
the selectivity is high) as weIl as the overall drug clearance. Thus the principal 
information that may be obtained from the in vivo pharmacokinetics is related to the 
overall drug clearance pattern. The 24 h total clearance time from skin indicated by the 
in vivo results for both of the ethanolamides HPPEEA (Fig. 4.25) and PEA (Fig. 4.27) is 
much faster than for compounds such as PlI (about 2 months) (Henderson and Dougherty, 
1992). It would have been informative if the in vivo pharmacokinetics of PlI could have 
been studied by fluorescence in a manner similar to that described here in order to permit 
a more direct comparison, but such a study was unfortunately not possible due to limited 
availability of PlI. A compound very similar to the ethanolamides, namely chlorin e6 
ethylenediamide (EDA), has been reported in which a similar fast clearance from Af mice 
was observed (46 h) (Gurinovich et al. , 1992). 
Thus the in vivo pharmacokinetics results show that the ethanolamides exhibited 
a fast clearance from aIl tissues. This is a requirement for a good PDT agent. 
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Neither ethanolamide exhibited any tumour tissue selectivity in Lewis lung 
carcinoma, as observed by both the in vivo (Fig. 4.25 and 4.27) and ex vivo (Fig. 4.28 and 
4.29) pharmacokinetics. Poor tumour selectivity by drugs in sorne animal-tumour models 
is not unusual (Henderson and Dougherty, 1992). Such negative results are often related 
to the model used. For example, a selection of metallo-naphthalocyanines have recently 
been shown to only partially localize in Lewis lung carcinoma (Shopova et al. , 1994). 
Further, it was recently observed that the same mouse breed as that used in this study is 
a poor model for demonstrating selectivity (Biolo, 1995). A large variation in tumour 
selectivity by photosensitizer drugs in different animals-tumour models is indicated in 
Table 1.2. Similarly Kostenich et al. (1993 ,1994) have found that different tumours in 
the same mouse model gave different results, for example chlorin e6 gave a TIM ratio of 
8.8 in the Ml tumours but the TIM ratio was only 6 in the type 45 tumours. These 
observations imply that more than one tumour type should be studied when investigating 
the pharmacokinetics of new drugs. The ethanolamide tumour selectivity was thus tested 
on another animal-tumour model, namely the Balb c mice with a lung adenocarcinoma. 
Tumour selectivity of PEA was exhibited in the ex vivo study of Balb c mi ce 
carrying the lung adenocarcinoma (Fig. 4.30). The tumour to muscle ratio (TIM) of 6 
observed can be considered to be quite acceptable because transplanted tumours in the 
Balb c mice model often exhibit low selectivity with TIM ratios of about 2 (Henderson 
and Bellnier, 1989). In other tumour-animal models the selectivity can be higher. For 
example, EDA which is similar to PEA, has a TIM of 14.4 in Af mice with a sarcoma 
tumour (Gurinovich et al., 1992). The TIM values in animal models reported in Table 
1.2 are generally between 4 and 8, with a few exceptionally high values such as BPD-MA 
at 19.2 (Richter, 1994). 
Skin photoreaction can be a problem during PDT if the drug concentration in the 
skin is high during phototherapy (Tralau et al. , 1989; Roberts et al. , 1989; and Henderson 
et al. , 1991). The photosensitization reaction will not be limited to the tumour if the ski n, 
which overlies the tumour contains substantial amounts of the PDT drug. Thus a large 
tumour to skin (T/S) ratio is required in order to minimize unwanted normal skin 
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photodamage. Although PEA exhibited high concentrations in the skin at 1 h, by 3 h 
when the tumour drug concentration peaked, the skin drug concentration had dropped to 
half that of the tumour, giving a T/S of 2. In Table 1.2 the literature values given for T/S 
ratios vary from 1 to 6 for different potential PDT agents. Another chlorin derivative, 
HPPH, has a T/S ratio of 6 (Bellnier, 1994). Therefore the T/S of 2 for PEA is in the 
typical range of most current PDT agents. 
In certain cases, the best treatment time may not be when the drug concentration 
peaks in the tumour. If the drug concentration in the skin is still high when the peak drug 
concentration in the tumour occurs, then there is still a risk of a skin photoreaction during 
treatment. Under su ch conditions, it may be preferable to photoactivate the tumour at a 
time when a lower total drug concentration is present in the tumour and skin, but when 
the T/S ratio is high. The time when the peak drug concentration is observed in the 
tumour is usually longer than that for the skin, for example 3 h for PEA in the lung 
adenocarcinoma tumour of Balb c mice and 1 h for the skin. While only a detailed 
human pharmacokinetic study would definitely decide what the optimal treatment time in 
human tumours, the animal model used in this study indicates that 3 h post injection 
would be a good time for PDT treatment when using PEA. 
5.3.4 Photosensitization activity of the ethanolamides 
Demonstration of photosensitization activity by direct measurement of 
photophysical parameters, such as <Dt. has only been performed in in vitro systems 
(McGarvey and Truscott, 1990). For potential PDT photosensitizers a biologically 
relevant system would be preferred. As discussed in section 2.1.4, photohemolysis can 
be used to estimate photosensitization activity in biological systems. 
The photosensitization activity of the ethanolamides can be estimated by 
photohemolytic studies. The procedure used is sometimes referred to as delayed 
photohemolysis sin ce the light induced damage occurs during a dark period after the light 
exposure (Pooler, 1984; Pooler and Girotti, 1986). The delayed photohemolysis method 
provides a rapid and simple assay to study the photosensitization ability of drugs towards 
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cell membranes. In tissues, the damage from photosensitization is often apparent several 
ho urs after the light treatment has ended, much the same as in delayed photohemolysis. 
The drug concentrations used in the photohemolysis study are of a similar order of 
magnitude to those typically found in tissues after administration of PDT drugs, namely 
values of Ilg g-l. Both ethanolamides (HPPEEA and PEA) exhibited high photohemolytic 
activity as compared to their parent molecules and to pHP (Table 4.8) . The 
photohemolytic activity of the ethanolamide and its parent molecule might be expected 
to be approximately the same since the porphin ring, which is responsible for the photon 
capture, is similar in both. A possible explanation for the higher activity of the 
ethanolamides may be the amphiphilic structure of these molecules (Bonnett and 
Berenbaum, 1989). Ben-Hur et al. (1993b) have shown that amphiphilic phthalocyanines 
had an order of magnitude higher photohemolytic activity than other phthalocyanines. 
The ethanolamide moiety provides a polar region on the PEA molecule, which is joined 
to the apolar porphin ring (see Fig. 4.12). Amphiphilic molecules may better penetrate 
red blood cell membranes and thus lead to higher cellular concentration due to their 
similarity to the amphiphilic phospholipids of membranes (Ben-Hur et al., 1993b). More 
photohemolytic damage would thus occur sin ce the amphiphilic sensitizer would be in 
proximity to the membranes. It is proposed that the amphiphilic nature of the 
ethanolamides may account for their higher photohemolytic activity. 
In summary, PEA was synthesized in gram size quantities with a purity of 95%. 
A new class of compounds, the porphin ethanolamides, demonstrate chemotherapeutic 
activity, but with activity lower than conventional chemotherapeutic agents, as expected. 
The twofold higher chemotherapeutic activity of HPPEEA compared to PEA supports the 
hypothesis that the ethanolamides, as do the nitrogen mustards, have a mono- or di-
functional reactivity based on the number of ethanolamide moieties present. PEA 
demonstrated significant localization in the lung adenocarcinoma of Balb c mice, but 
neither PEA or HPPEEA localizes in Lewis lung carcinoma. It is suggested that Lewis 
lung carcinoma may be a poor tumour model to study these compounds. PEA and 
HPPEEA demonstrated higher photohemolytic activity than their respective parent 
molecules and pHP. The high photohemolytic activity of the ethanolamides may be due 
to the amphiphilic nature of these compounds. 
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Chapter 6 Conclusions 
A synthetic method was developed that was capable of producing large quantities 
of an ethanolamide derivative of chlorophyll a, pheophorbide a ethanolamide. This new 
compound shows high light absorption in the far red, with a molar extinction coefficient 
of 2.64 x 104 M-1 cm-1 at 665 nm. The photosensitization activity of PEA, as determined 
by photohemolysis, is high. The tumour tissue selectivity is relatively high (T/M = 6.0) 
in Balb c mice at 3 h with the lung adenocarcinoma; however PEA did not show 
selectivity toward Lewis lung carcinoma in B6D2F1 or SKH-HR1 mice, indicating that 
this model is unsuitable for the assessment of this compound. 
PEA has low toxicity (> 166 mg kg-1 daily for 3 days) which suggests a high 
therapeutic index. It is not known why this ethanolamide has such low toxicity toward 
normal tissues, but such low toxicity may indicate that PEA is bound in a non-toxic form 
in normal tissues. 
Photohemolytic studies indicate that PEA has higher than expected 
photosensitization activity . It is suggested that the amphiphilic nature of this new 
compound may permit it to be more closely associated with cell membranes, resulting in 
increased membrane damage via photosensitization. 
Pharmacokinetic studies in both in vivo and ex vivo indicated rapid clearance of 
PEA (approximately 24 h) . The amount of PEA in the skin was low (T/S = 2.0) when 
the peak levels were measured in the tumour of the Balb c mice. The lower skin 
concentration of PEA would tend to reduce ambient light induced skin photoreactions 
after PDT treatment, a favourable feature . 
For PEA to be a potential PDT agent, it must demonstrate both photosensitization 
activity and selective tumour localization. Its photosensitization ability, indicated by the 
photohemolytic activity, and its selective localization in the Balb c adenocarcinoma, 
support the potential of PEA as a PDT agent. Based on this study using 10 mg kg-l of 
PEA, the best time for PDT treatment in mice would be at 3 h post injection. 
Animal model studies indicate that PEA is able to prevent the formation of 
secondary tumours in Lewis lung treated animaIs, indicating that the new drugs can stop 
metastasis. The MTT cytotoxicity studies indicated that PEA has chemotherapeutic 
activity, which is lower than the chemotherapeutic agent adriamycin. The animal 
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chemotherapeutic studies suggest sorne weak chemotherapeutic activity. 
The ethanolamide compounds have a chemotherapeutic activity but at a lower level 
than the nitrogen mustards. PEA is representative of the ethanolamide derivatives that 
are a promising new class of dual action PDT agents that demonstrate both 
chemotherapeutic and photosensitization activity. 
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